Category Archives: Zenosense Inc. ZENO

Zenosense Inc. (ZENO) Virus Detection Devices to be Time, Money and Life Savers

April 29, 2015

Methicillin-resistant Staphylococcus aureus (MRSA) is a resistant form of bacteria that stakes an infamous claim to causing infection in a variety of areas on the human body. Commonly, MRSA manifests itself in the form of boils, sores or abscesses. The MRSA bacteria is unique among staph infections because it is resistant to today’s pervasively prescribed forms of antibiotics. MRSA skin infections occupy an extenuating range from elementary to life-threatening. Due to being knowns as unpredictable and difficult to treat, MRSA is widely referred to in clinical circles as a “Superbug.”

MRSA in the form of skin rashes spreads through the resistant bacteria entering the body. While staph is common, it can cause infection when it gets into the blood via cut in the skin. This form of bacteria has evolved through generations as cultures have over prescribed and subsequently overused antibiotics to treat common colds, viruses and influenza (the flu). Even when antibiotics are appropriately used to treat bacterial infections, they cause bacteria to adjust, making them more resistant. With the MRSA constantly changing, it complicates the task for researchers to develop antibiotics that will effectively fight it.

The symptoms of MRSA found on the skin are commonly red and swollen. These infections can also look like pimples or spider bites and are pus-filled. Left untreated, infection can spread to the blood. As the infected blood moves through the body, infection of the joints, bones, heart valves and lungs can occur and result in organ failure. Other symptoms come in the form of chills, fever and cough. Patients with weak immune systems, those who live and work in care centers, such as day care centers, jails, and retirement homes are at particular risk.

Zenosense Inc. (OTCQB: ZENO) holds an exclusive global license agreement for developing and marketing medical devices within hospitals and primary healthcare facilities. The company’s devices target the early detection of both deadly bacteria like MRSA and some cancers through detection within a person’s breath. Two devices are currently being developed. One is a device intended to detect the MRSA “Super-Bug” and the other is intended to detect Lung Cancer. Through the commonly used Electronic Nose technology platform, the ZENO devices are being designed to detect volatile organic compounds (VOC’s) present in the exhaled breath of patients.

Company experts in the fields of nanotechnology, sensors, high-level mathematics, molecular biology and biochemistry are currently engaged in work necessary for product development.

For more information on the company, visit www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

Zenosense, Inc. (ZENO) Continuous Scan Detection Technology Could Be the Most Important New Tool in the War Against MRSA

April 22, 2015

We’ve had a good run for the last seven decades or so, being able to defeat almost all microbial infections with a growing variety of powerful antibiotics, but the proliferation of antibiotics has also led to underdosing and careless prescription, directly driving the evolution of antibiotic-resistant microbes. In fact, most hospitals routinely overuse antibiotics according to recent analysis by leading healthcare providers alliance, Premier (NASDAQ:PINC), in which they reviewed data from their sizeable membership and found that the inappropriate and redundant use of combinations of the most common therapies was prevalent in almost 80% of all facilities, also amounting to $13 million a year in excess spending.

Many in the medical community are becoming increasingly alarmed by the looming threat that the evolution of multidrug resistant and now even totally drug resistant microorganisms pose. The billions per year in excess healthcare costs alone resulting from the rise of drug resistant/immune microorganisms is a serious problem, but the potential impacts to clinical patient outcomes and loss of human life, could be systemically staggering. This is especially true in highly specialized and developed economies, whose very organizational strengths make them particularly vulnerable to the kind of sporadic chaos that the rise of drug resistant/immune bacteria could create.

We are facing a possible future where such microbes, which have adapted through genetic mutation to underdosed or overused antibiotics across huge numbers of subjects, may shatter the antibiotics paradigm itself, making most, if not all of the available therapies in existence today completely useless. Compounding this problem is the growing incident rate of HAIs (hospital-acquired infections), which are conservatively estimated as affecting 5% of all patients according to the CDC’s own numbers, and which are associated with over 23k deaths per year in the U.S. alone, as well as 100k plus deaths per year worldwide.

One of the most troubling bugs in the mix is MRSA (Methicillin-resistant Staphylococcus aureus), because it is responsible for numerous infections that are difficult to treat and because it is highly resistant to the standard beta-lactam class antibiotics, including typically prescribed penicillins (even oxacillin), as well as the cephalosporin group. MRSA is of particular concern in hospitals or extended care facilities where patients who have open wounds or invasive devices, as well as patients with compromised immune systems, are at a statistically much higher risk of infection. Estimated as being responsible for around 11k deaths and 80k invasive infections in the U.S. alone each year, costing over $2.5 billion in excess healthcare costs, MRSA has been clearly identified by the CDC (alongside other drug resistant bacteria), as being a prime target for advanced detection technologies, which may be one of the only truly effective ways to curb its spread. Moreover, the ability to accurately and quickly detect sources of contamination may eventually lead to improved use of antibiotics in general, greatly reducing their application where it is unnecessary and helping to get them applied more rapidly when they are needed, ultimately helping a great deal when it comes to stemming the tide of drug resistant bacteria, directly at the source of its adaptation.

While newer technologies in use today, like the GeneXpert® system from molecular diagnostics company Cepheid (NASDAQ: CPHD), have taken MRSA detection times down from a few days to only a few hours (or even as low as 66 minutes), allowing for the reduction of costly, presumptive patient ICU isolation, as well as nursing labor, such systems still require swabbing and unit culturing. A similar approach by Switzerland-based diagnostics developer Roche (OTCMKTS: RHHBY), with their cobas® MRSA/SA Test using the cobas 4800 system, while providing highly accurate and real-time polymerase chain reaction based detection, still requires swabbing the patient and then running the vial through expensive hardware to do the detection.

This unfortunate reality is where innovative detection device development company Zenosense (OTCQB: ZENO) comes into clear and sharp focus, as they are currently co-developing a revolutionary new series of devices capable of accurately discriminating the signature VOCs (volatile organic compounds) associated with MRSA/SA, as well as lung cancer, in real-time by processing the air and the patient’s exhaled breath. Working with renowned sensor developer, Sgenia Group’s dedicated subsidiary, Zenon Biosystem, Zenosense plans to market these devices directly to hospitals and other healthcare settings where they can provide the kind of early detection needed to save huge sums of money and countless patient lives.

Such electronic nose technology is somewhat new but there have been several applications of it in recent years, including for creating sniffing devices that can detect the chemical signature of explosives. And despite existing devices, like the Airsense system installed on the ISS (international space station), being bulky and prohibitively expensive, such devices have proven to be of immense value for doing real-time detection that does not require some kind of sampling and culturing or other cumbersome test protocol.

The Zenosense device’s core technology, an algal (water) based chip under license to Zenosense from Sgenia, has already been developed and proven. Pairing this platform with a single, cheap, off-the-shelf gas sensor and the company’s own sophisticated processing software, allows the Zenosense device to achieve the same analytical capability as up to 32 sensors, which would require their own supporting processors, circuit boards, and power supplies. The result is an inexpensive and lightweight detector that can be worn or placed in a fixed position in a patient’s room, providing continuous, accurate scans that will take the guess work and hassle out of MRSA detection.

A potential game changer that could help us head off the “end of antibiotics” scenario that has the healthcare community spooked, the Zenosense MRSA/SA detection platform also has the ability to actively learn target VOC signatures across the spectrum, giving it powerful abilities that could make it a virtually indispensible feature of all healthcare facilities on earth one day.

To learn more about the company, please visit www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

Zenosense, Inc. (ZENO) – A Healthcare Tech Company on a Mission

April 14, 2015

Valencia, Spain-based Zenosense is embedded in the emerging healthcare technology arena. Since its establishment in 2008, the company has been focused on developing detection devices.

Nowadays, Zenosense is developing functioning, cost-effective medical devices that will identify, very early on, lethal bacteria or cancers in a patient’s expelled breath. The company has its eye on co-developing two key devices with strategic partners; one device is intended to detect lung cancer and the other to detect the Methicillin-resistant Staphylococcus aureus (MRSA) “Super-Bug” in hospitals and clinical settings.

Considering that there is less than a 20% chance that lung cancer cases will be detected in the fairly treatable first stage of the disease, Zenosense has been a company on a mission lately with its laser focus on co-developing its lung cancer detection device with Zenon Biosystem. Zenon is member of The Sgenia Group, and going all out as Zenosense’s contracted development partner.

Zenosense and Zenon revealed last November that they were building a prototype device for testing during a lung cancer detection trial that would ultimately determine if the device should make its market debut. Since then, Zenon has been striving to create the partnerships needed to perform the planned trial. Zenon has also undertaken the task of manufacturing the tangible prototype. To meet the protocol design terms of the lung cancer detection trial, Zenon will produce two pre-market devices of matching design to ensure that the results of the trial can be duplicated.

Zenosense feels that a breath-analyzing lung cancer detector that is proven to meet or surpass the accuracy of low-dose Computed Tomography (CT) scanning will create wide appeal and subsequent demand. They also believe that the successful development of a high-quality, non-invasive, cost-effective early detection screening method will likely offer major improvements in survival rates and decreases in mortality rates.

For more information, visit www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

Zenosense, Inc. (ZENO) Addressing Lung Cancer Survivability with New Technology

April 7, 2015

Lung cancer is one of the most fatal types of cancers in the world today. In 2015 alone, the American Lung Association estimates that more than 158,000 Americans will die from lung cancer, outpacing the combined fatality numbers of colorectal, breast and prostate cancers. Despite these somber figures, many people whose cancer has been detected in the early stages have been cured. According to the American Cancer Society (ACA), more than 430,000 people are alive today despite having been previously diagnosed with lung cancer, largely as a result of early diagnosis. Zenosense, Inc. (OTCQB: ZENO), through its developmental commercial lung cancer detection devices, is closing in on a way to greatly increase survivability.

One of the most important factors to consider when weighing the survivability of lung cancer is the stage in which it is originally detected. Studies by the ACA indicate that patients who have their cancer diagnosed in Stages IA or IB have a survival rate of just less than 50 percent, but those numbers quickly take a turn for the worse in later stages. If detected in Stage IIA or IIB, for example, survivability drops to just 30 percent, which is a perfect illustration of the importance of early detection.

Unfortunately, current diagnostic tests are limited in their effectiveness. The most commonly utilized screening method is a low-dose spiral CT scan, but the costs associated with these tests can often lead patients to waste valuable time before receiving the critical diagnosis. Zenosense’s non-invasive early detection method, which is currently in clinical trials, could be just the breakthrough to turn the corner on lung cancer survivability.

Using inexpensive sensors, the company aims to detect distinctive volatile organic compounds associated with lung cancer in the exhaled breath of patients. With methods similar to those used by prostate cancer detecting canines, these electronic detection devices could represent a significant step toward a major healthcare breakthrough.

With less than 20 percent of lung cancer currently being detected in the relatively treatable Stage I, the medical market should be extremely receptive of a more effective diagnostic tool. As a result, the company has expressed tremendous confidence that a cost-effective lung cancer detector with accuracy meeting or exceeding that of low-dose CT scanning will have widespread appeal in the medical community. As the company continues testing in university hospitals around Madrid, Spain, be on the lookout for significant opportunities.

For more information on the company, visit www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

Zenosense, Inc. (ZENO) Prepares to Sniff Out MRSA

March 30, 2015

Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium that’s associated with several dangerous infections. Particularly troublesome in nursing homes, hospitals and prisons, MRSA is difficult to treat with standard types of antibiotics and, therefore, more dangerous than other bacterial strains. While time intensive cultures have traditionally been used to diagnose the infections, quicker tools are needed to adequately prevent the spread of the bacteria and minimize treatment costs. Zenosense, Inc. (OTCQB: ZENO), through the development of its low-cost electronic “nose” device, is working to revolutionize the market.

By using a low cost gas sensor as a starting point, Zenosense is developing an affordable diagnostic tool that acts like a smoke alarm for MRSA. The sensor will continuously scan the air for infection-specific volatile organic compounds (VOC), which will provide administrators with immediate feedback that should be more effective in containing MRSA outbreaks.

According to the CDC, MRSA infections impact an estimated 75,000 people annually. While these patients generally have a high survivability rate, the infections can be particularly dangerous if compounded with other health problems. For that reason, it is imperative for healthcare facilities to detect outbreaks of MRSA in their early stages in order to limit their spread. Late detection of MRSA outbreaks has significant costs and dangers. Through the use of the company’s specialized detection device, hospitals will be able to improve their probability of early detection, which will open the door for proactive protective measures and significantly reduced costs.

While electronic “nose” devices currently exist on the market, they are too bulky and expensive for widespread use in medical facilities. Zenosense, through the continued development of its detection device, is preparing to service a multi-billion dollar industry while addressing substantial health and safety concerns.

The company’s MRSA device is intended to be produced in both wearable and fixed position forms. With the company continuing towards the completion of development, look for Zenosense to make significant waves in the diagnostic and detection industry in the years to come.

For more information on the company, visit www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

Zenosense, Inc. (ZENO) Gaining Steam as Lung Cancer Detection Trial Ramps Up

March 23, 2015

Zenosense has been working with a large university hospital in Madrid, Spain to test the effectiveness of its specially designed volatile organic compound (VOC) detection techniques. The collaboration is particularly promising, because, in addition to its work with Zenosense, the university hospital has been directly involved in a number of published studies focusing on the detection of VOCs in order to better identify various respiratory pathologies.

While the 400 subject trial will serve as an excellent proof of concept, Zenosense hopes to considerably increase the size of its tests following positive initial results. The company expects the initial trial to take nine months and involve four distinct groups of subjects including healthy smokers, non-smokers and those with diagnosed lung cancer and Chronic Obstructive Pulmonary Disease. The company has already been approved by the ethics committee of the university hospital, meaning that broadening participation to include a host of other public hospitals throughout Spain is possible without the need for further approvals.

If the trials prove successful, Zenosense will be one step closer to taking its revolutionary diagnostic systems to the market. By allowing for superior early detection of lung cancer through non-invasive means, there’s little doubt that the company’s devices would be in a great position to experience tremendous demand. The company predicts that having a way to improve early detection through cost effective screening techniques could offer noticeable improvements to the survivability rates of lung cancer and similar ailments.

VOC detection is a tried and tested method of diagnosing diseases. Just as highly trained dogs have been able to recognize prostate cancer-specific VOCs with up to 98 percent accuracy, Zenosense’s use of a common Electronic Nose technology platform puts it in a great position to improve diagnostic accuracy for a wide range of diseases.

As the company’s trial continues to ramp up, look for Zenosense to make some major waves in the medical and diagnostic industries in the near future. With the possibility of dramatically improving the survivability of some of the world’s most deadly illnesses and servicing multi-billion dollar industries, the sky could be the limit for this detection device development company.

For more information on the company, visit www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

Zenosense, Inc. (ZENO) Aims to Save Lives with Rapid Detection Medical Devices

March 13, 2015

Zenosense holds an exclusive global license agreement to develop and market medical devices primarily for hospitals and primary healthcare facilities. By identifying specific markers found in individual’s exhaled breath, Zenosense’s devices strive for the early detection of deadly bacteria as well as some cancers.

The company is currently developing two devices – one intended to detect “Super-Bug,” or Methicillin-resistant Staphylococcus aureus (MRSA), and the other to detect lung cancer. The devices utilize a common Electronic Nose technology platform that analyzes Volatile Organic Compounds (VOCs) present in the exhaled breath of patients.

MRSA infections account for approximately 23,000 deaths per year in the United States and are diagnosed with testing procedures that can take up to three days to complete. Zenosense, in collaboration with partner Zenon Biosystem, is developing a lower cost system that dramatically quickens discovery times.

The electronic process of detecting the disease is based on natural processes. For instance, trained dogs are able to detect prostate cancer in urine with near complete accuracy. This is done by leveraging the innate sophistication of the approximately 200 million olfactory cells in canine noses. This natural, learned detection is similar to Zenosense’s technology in that it uses an infinite number of sensors and software that in effect ‘learns’ to recognize VOCs of concern.

Experts in nanotechnology, sensors, high-level mathematics, molecular biology and biochemistry are central to the development of the company’s technology, as are established partnerships with hospitals and universities in the areas of microbiology, infectious disease and chromatography, among others.

As the company continues to advance the development of its technologies, Zenosense strives toward its ultimate goal is to sell its medical detection devices to care facilities in the healthcare sector and revolutionize the detection of deadly bacteria and cancer.

For more information visit www.zenosense.net/

Let us hear your thoughts: Zenosense, Inc. Message Board

Zenosense, Inc. (ZENO) Developing Improved Antibiotic-Resistant Infection Detection Solution

March 3, 2015

Methicillin-resistant Staphylococcus aureus (MRSA) infections account for an estimated 23,000 deaths per year in the United States alone. While current diagnostic testing procedures can take up to three days, Zenosense, Inc. (OTCQB: ZENO), in concert with development partner Zenon Biosystem, is developing a new, low cost sensor platform that will help decrease diagnosis times and, potentially, save the lives of millions of patients around the world.

The company’s technology will depend on the presence of Volatile Organic Compounds (VOCs), which are emitted by MRSA infections long before other symptoms become visible, making earlier intervention a distinct possibility. The diagnostic tool is currently being developed in two unique forms, including a wearable device designed to be positioned directly on patients and medical staff, as well as a fixed device engineered to consistently monitor a specified area in which the potential for infection is present, such as a hospital room.

According to reports from the Center for Disease Control, while MSRA infections in the community are typically relatively minor, those in medical facilities commonly cause life-threatening bloodstream infections, pneumonia and surgical site infections. The contaminations are particularly dangerous because the presence of two subpopulations, of which only one may be resistant to antibiotic treatment, can seriously hamper the accuracy of existing detection methods. Through its unique VOC sensor, Zenosense is preparing to address the serious flaws present in current MSRA detection options.

Zenosense began its development program of an MRSA infection sensing device in December 2013. Phase I activity on the project includes substantial engineering work, as the company expects greater than 90% sensitivity for the detection of MRSA-specific VOCs in patients.

As antibiotic-resistant bacteria threatens to return us to the time when simple infections were often fatal, the early and accurate detection of these contagions is the only way to minimize health risks. With Zenosense continuing its development of a revolutionary VOC sensing MRSA diagnostic device, the company could be in position for massive demand from the global healthcare industry in the near future.

For more information on the company, visit www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

Zenosense, Inc. (ZENO) MRSA/SA Detection Device to Benefit as Obama Admin Calls for Doubling of Federal Spending to Address Rise of Antibiotic-Resistant Bacteria

February 25, 2015

HAIs (health care-associated infections), like dangerous and increasingly antibiotic resistant MRSA/SA (Methicillin-resistant Staphylococcus aureus) infections, are increasingly being cited as a major concern among hospital staff and administrators. The growing alarm is due in part to how these bacteria can colonize a patient or surface in a persistent fashion and then spread, causing serious infections in otherwise relatively minor wounds or inside a patient’s body, where the already problematic infection is even more difficult to treat.

Mortality figures are already quite alarming, with the CDC’s rough estimates showing around two million Americans infected per year by some kind of antibiotic-resistant bacteria, leading directly to somewhere in the neighborhood of twenty three thousand fatalities and almost one hundred thousand associated fatalities. The growing use and abuse of antibiotics when they are not needed is accelerating the evolution of bacteria and there may now be a cascade failure of the existing antibiotic treatment paradigm, making early, accurate detection of infections like MRSA/SA more important than ever before.

With early detection also being a key factor for survival rates, the MRSA/SA detection system currently being developed by Zenosense, via a partnership with leading Spanish sensor manufacturer Sgenia Group’s wholly-owned subsidiary, Zenon Biosystem, could prove to be a real life saver. For ZENO, the device will no doubt become a serious money maker as well, with health care facilities around the globe invariably turning to the company’s technology in order to create a necessary security envelope, which will ultimately function very much like existing smoke detection systems.

Zenosense’s MRSA/SA detection device, when commercialized, will be formatted as both a stationary room-based detector and a battery-operated wearable, designed to be either carried by staff, or by specific patients. The device continuously monitors for carefully targeted VOCs (volatile organic compounds) and sounds an alarm buzzer upon a successful detection, long before an infected patient begins to demonstrate signs of an infection. The device uses a sophisticated, proprietary software platform and relatively cheap off-the-shelf hardware sensors configured as a virtual multi-sensor array. This virtual array design allows a single-chip architecture to continuously run multiple scans while simultaneously discriminating against background VOCs beyond the target scope, making the device cheap, yet highly accurate.

Such a device would be cost-effective enough to roll out across the country and/or globally in a variety of healthcare, assisted living and eventually even home settings, bringing life-saving early infection detection to the masses. With the recent move by the Obama Administration to seek nearly double last year’s federal spending on addressing antibiotic-resistant bacteria’s rise, as set forth in the current budget for fiscal 2016, there will be plenty of money floating around out of the approximately $1.2 billion being sought, for funding development and commercial roll out of such devices as the one Zenosense is readying.

With over half the money from the 2016 National Strategy for Combating Antibiotic Resistance budget going to the NIH, CDC and VA, to cover a range of antibiotic-resistant bacteria issues, ZENO is in a prime position to capitalize on the logistically inefficient current modality of clinical laboratory testing for MRSA/SA presence. With a variety of costly/ slow and cumbersome lab testing being the currently accepted standard, a device like the one ZENO is developing, which can simply sniff the air for VOCs, has the potential to reshape the face of the MRSA/SA response curve dramatically.

The emergence of once-weekly intravenous doses of dalvance and oritavancin as an alternative to daily vancomycin treatment means that MRSA/SA, if detected early, could start to be cleaned up more readily, reducing the overall incident rate in the U.S. significantly. Unfortunately the cost of such treatments is still rather steep, putting even more pressure on the industry to find ways to detect the infection earlier, when it can be treated more effectively and quickly, thus reducing the overall cost of a given treatment schedule.

One can easily see the ZENO early detection device playing a key role in bringing about a new paradigm for handling MRSA/SA across hospitals in the U.S., and the same benefits of this low-cost, highly effective platform technology, means that institutions like schools and universities, as well as health clubs and sports franchise locker rooms could also benefit.

For more information, visit www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

Zenosense, Inc. (ZENO) Looks to Revolutionize Early Lung Cancer Diagnosis

February 18, 2015

Less than 20 percent of lung cancer cases are detected in the relatively treatable Stage I, but healthcare technology company Zenosense, Inc. (OTCQB: ZENO) is hoping to change that. On December 16, 2014, the company announced its intention to conduct a 400 person lung cancer detection trial in collaboration with a university hospital near Madrid, Spain. Using its proprietary non-invasive, cost effective detection devices, the company aims to identify distinctive volatile organic compounds (VOCs) by analyzing patients’ exhaled breath.

Zenosense is hoping to use a technique based on natural processes to decrease the costs associated with lung cancer detection. Sniffing out diseases is a proven diagnostic method, as highly trained dogs have been used in the past to recognize the VOCs associated with prostate cancer with 98 percent accuracy. In the same way, the company’s device uses a great number of sensors to detect VOCs that are unique to a particular illness, such as lung cancer.

“I believe that a cost-effective lung cancer detector proven as meeting or exceeding the accuracy of low dose Computed Tomography (CT) scanning will have wide appeal and be in significant demand,” said Carlos Gil, Chief Executive Officer of Zenosense.

Zenosense expects the trial to take nine months, during which the company will examine samples from multiple groups to ensure proper functionality. If successful, the company intends to increase the size of the trial population in the future.

According to the American Cancer Society, there will be approximately 221,000 new cases of lung cancer, as well as an estimated 158,000 lung cancer related deaths, in the United States during this year alone. The same report indicates that patients who had their cancer diagnosed during Stage I development had an increased 5-year survival rate of approximately 61 percent over those who were diagnosed in Stage II.

With Zenosense’s lung cancer detection trial officially scheduled, a significant step forward in diagnostic techniques and lung cancer survivability could be just around the corner.

For more information on the company, visit www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

Zenosense, Inc. (ZENO) Positioned to be First to Commercialize Breath-Based Lung Cancer Detection Device

February 10, 2015

In a report published by Transparency Market Research, the global cancer diagnostics market was estimated four months ago as being on track to grow at a CAGR of 7.6% over the next five years to around $169 billion. The increasing prevalence of lung cancer, the second most common type of all cancers, will continue to be a strong underlying driver of the diagnostic market’s growth. China is seen as one of the fastest growing markets in this segment, considering the incident rate is rising ferociously according to the latest World Health Organization analysis, which cites the fact that lung cancer is now the most common type diagnosed among Chinese males and has rocketed up to become the top overall cancer killer in the country.

The story of a beautiful young 20-year-old Chinese girl, Li Na, recently went viral online across China, detailing her courageous battle against and eventual death at the hands of lung cancer. This story of an attractive young girl, cut down in the prime of her life by the ravages of lung cancer (including a leg amputation at the thigh due to associated osteosarcoma), has created a much sharper awareness among Chinese people far and wide regarding to the country’s growing problem with cancer, as well as air pollution. The highly publicized smog in Beijing continues to be a prime and oft-cited example of the kinds of environmental hazards and principal causes behind the alarming rise of lung cancer cases in China. Of course, high rates of smoking among Chinese men is also a major contributing factor and given that early detection of cancer is perhaps the most important element of a solution when it comes to saving lives, the early detection and diagnostics market, particularly for lung cancer, has a very bright future indeed – both at home here in the U.S. and abroad.

The recent buzz about a lung cancer breathalyzer testing system developed by University of Cambridge researchers and under further development towards commercialization by a university spin off, Owlstone Nanotech, shows that breath-based detection technology is finally coming into its own. Given that early detection of lung cancer results in a roughly 71% survival rate and that less than 15% of cases today are ever detected early, the demand for a robust testing system is extremely high within the medical community. The advent of a commercial device would mean the possibility for comprehensive testing and Owlstone has floated a potential target date for devices to start appearing in medical clinics in the UK of around September 2016, with a commercial product possibly becoming available sometime in 2017.

Much farther along the commercialization pathway in bringing a breath-based lung cancer detection device to market is publicly traded Zenosense, Inc. (OTCQB: ZENO), which is currently trading at a highly accessible share price of around $0.18/share. Zenosense has an exclusive contract with European sensor developer Sgenia Group, whose dedicated subsidiary, Zenon Biosystem, is developing both a lung cancer detection device and a MRSA/SA (Methicillin-resistant Staphylococcus aureus) detection device based on their established, patent-pending sensor technology.

Sgenia Group has an impressive track record in sensor technology as well, having established itself firmly in European markets via efforts like their development and supply of cutting-edge sensors to the $19 billion plus Tokamak nuclear fusion project. This same sensor hardware and software was later adapted and successfully utilized in producing an algal contamination detector capable of scanning for targeted VOCs (volatile organic compounds) in water supplies, technology which has been and is being rolled out across Spain. The proprietary sensor hardware and electronic processing technology developed by Sgenia is extremely accurate and yet cheap in the currently under development applications, leveraging key design advances and a software-based virtualization technique in order to create a platform that is both high-fidelity and cost-effective.

Zenon Biosystem’s development of MRSA/SA and lung cancer detection devices using this technology has gone extremely well thus far, with a set of pre-commercial lung cancer detectors having been successfully manufactured as of November 2014, and a subsequent 400-person detection trial initiated at a university hospital the following month. Given that the MRSA/SA prototype already produced a sensibility detection rate of over 95% last year, confidence is high at ZENO that they have the pole position when it comes to commercializing a lung cancer detector that uses exhaled breath.

Moreover, the company has already seen key device advancements in the areas of screening out background VOCs that would be considered noise when it comes to making an accurate diagnosis, using molecular sieves and nanometric sensing mesh. Similar advancements by Zenon with the development of new metal oxide materials and combinations thereof, not currently seen in commercially available sensors, as well as the design of a complementary quartz crystal sensor that uses a gas sorbent substrate and associated micro gas chromatography chip for pre-detection screening, also give the company a considerable edge.

If Zenosense can bring a breath-based, cost-effective lung cancer detection device to market ahead of the competition, the company could be raking in the dough amid a booming global cancer diagnostics market.

For more information, visit www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

Zenosense, Inc. (ZENO): The End of Antibiotics Marks the Beginning of an Early Detection Bull Market

February 3, 2015

While electronic sniffers have been in use for quite some time now to detect bacteria in cultures, cost as well as the size of such devices has largely prohibited their proliferation throughout the healthcare system where staph infections have become an increasingly prominent concern for patients and healthcare workers alike. MRSA, or methicillin-resistant SA, in particular has become a cause for serious concern, due to its having rapidly evolved extremely strong and often unassailable resistance to beta-lactam antibiotics like penicillins and cephalosporins, subsequently leading to tens of thousands of deaths and hundreds of thousands of difficult to treat infections each year.

With around an estimated 10k deaths in the U.S. alone each year linked to MRSA/SA infections, the looming specter of rapidly evolving MRSA and other bugs, a direct response to overuse and often misuse of antibiotics, has caused many in the medical community to hypothesize that we may be witnessing the potential end of antibiotics as we know it. Compounding the problem is the fact that the highest prevalence of cases is among patients with open wounds or invasive devices, especially if such patients already have weakened immune systems. This means that there is an entire class of high-risk patients for whom early detection is vital if there is any hope at all of saving the patient when they do get a serious infection, even with aggressive treatments like quinazoline, a newly developed (now in preclinical testing) class of chemical compounds which may be able to effectively treat MRSA. It will take considerable time to develop and get promising treatments like quinazoline out to the front lines and for now doctors have been turning more and more to highly toxic and severe alternatives like colistin, which despite unavoidable kidney damage, is sometimes the only way to save the patient.

Such harsh alternatives are increasingly dangerous the further along a given patient’s infection is and precise, early detection/treatment is also fundamental to slowing down the evolution of various resistant bacteria in the aggregate, as not allowing a colony of bacteria to flourish and then jump to a new host is essential to slowing its evolution. The CDC estimates that on the whole, some 2 million people are infected every year with some type of antibiotic-resistant infection, resulting in over 23k fatalities. Naturally, the demand for ways to detect such infections early on, so that they may be delimited and combated effectively, is increasingly becoming the major focus.

Zenosense is at the forefront of the effort to curb the spread and evolution of antibiotic-resistant bacteria, having pioneered the development of Sgenia group division, Zenon Biosystem’s algal (water) sensor platform under contract. Designed as a cost-effective solution that can be deployed as both a wearable/bedside device and fixed device to monitor a room, the company’s MRSA/SA detector based on the Sgenia technology developed by Zenon, pairs a single off the shelf commercial sensor with a proprietary Sgenia chip and powerful mathematical processing software, effectively yielding a multiplicity of virtual sensors that can continuously scan for precise volatile organic compound (VOC) markers produced by a MRSA/SA infection. The company is also developing this same revolutionary sensor platform for lung cancer detection and has already manufactured a pre-commercial lung cancer detection device, having subsequently launched a 400-person trial. It is not unthinkable that this sensor platform could one day be developed for yet more detection roles, as the core VOC sniffing technology lends itself quite readily to additional potential applications.

The MRSA/SA detection prototype being developed by ZENO has already achieved one of the company’s main development goals by having successfully hit 95%-plus sensibility detection rates in a series of tests conducted in a clinical setting. Moreover, the device has proven to consume very little power, lasting for an entire normal work shift on a single battery charge, making it ideal for per-patient use in a healthcare setting. A mains powered unit for doing room-based continuous detection should be equally cheap and cost-effective, providing the perfect answer to monitoring patients who are known to be at risk, especially in typical high-risk areas like nursing homes or wherever extended care of high-risk patients is normal.

The VOC signature spectrum analysis of this detection platform is quite precise as well and the ability to accurately discriminate from background VOCs in a roughly 10 foot bubble around a potentially infected patient means the device works like a continuous MRSA/SA smoke detector, producing an audio and visual warning whenever a successful detection of active infection is made. Such a device, which would detect infection and alert healthcare workers before the patient even begins to show signs of infection, would be a real game changer. Moreover, there is potential with the highly-sensitive Sgenia technology to eventually discriminate MRSA from SA as well, saving even more time, money, and no doubt, lives.

Zenosense has a clear first-mover advantage co-developing and marketing cost-effective detection devices for MRSA/SA and lung cancer. There is abundant need for the technology and demand shows no signs of diminishing for the foreseeable future.

To get a closer look at Zenosense, visit www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

Zenosense Inc. (ZENO) On the Heels of Early Cancer Detection Device Breakthrough

January 27, 2015

Any person diagnosed with cancer or any medical practitioner intimate with the study of this disease has learned that one of the most critical pieces of data for determining prognosis is the stage the cancer is in when first discovered. The more advanced the cancer stage at diagnosis, the lower the survival rate. The earlier the stage when discovered, the greater the chances of survival. To simply state, ‘the earlier the better,’ could easily be called as the understatement of the century. Our inquiring minds beg for answers to logical questions preceded with, ‘If only…’ or ‘What if there were a way…’

Zenosense Inc. (OTCQB: ZENO) is a company that not only asks, ‘What if,’ they are a company that devotes its time, attention and resources on producing an answer. Specifically, ZENO is committed to developing a non-invasive, cost-effective early detection screening method for detecting lung cancer. Long term, shareholder value intentions are believed to offer noticeable improvements in survival and mortality rates.

The company operates on the cutting edge of executing on the challenge of developing practical, cost-effective medical devices that will detect at the earliest of stages, deadly lung cancer bacteria and other cancers in a patient’s exhaled breath. And as would be expected, the promising news coming from company development efforts is generating positive activity and excitement.

In November of 2014, ZENO announced plans to manufacture a pre-market prototype device that would be evaluated during a lung cancer detection trial in a clinical setting. Zenon Biosystem, Zenosense’s development partner, assumed a leadership position in a project that would be responsible for manufacturing the prototype. In preparation for the planned trial and to meet the standards of the trial’s protocol design, Zenon planned to manufacture two pre-commercial devices of identical design to ensure that trial results could be duplicated. A month later, Zenon announced that it would be collaborating with a university and a large university hospital in Madrid, Spain on a nine month long lung cancer detection trial that will facilitate clinical tests on breath samples from 400 people.

Zenosense feels that a cost-effective, breath-analyzing lung cancer detector that is proven to meet or exceed the accuracy of low-dose Computed Tomography (CT) scanning will have broad appeal and demand. As a result, company development efforts have welcomed the news that a team of university research scientists and their hospital have recognized the potential for the technology. A positive outcome from the planned lung cancer detection trial will be a significant step toward a major healthcare breakthrough and quite possibly provide a much needed answer to the question, ‘What if…’

For more information on the company, visit www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

Zenosense, Inc. (ZENO) Proceeds with Lung Cancer Detection Trial

January 21, 2015

Presently, only a small amount of lung cancer cases are spotted in the relatively treatable first stage of the disease – less than 20%. Now, what if a non-invasive, cost-effective early detection screening method were developed? It will likely offer noticeable improvements in survival rates and decreases in mortality rates. This is where Zenosense comes in.

Zenosense, an emergent healthcare technology company, has taken on the challenge of developing functioning yet cost-effective medical devices that will detect, early on, deadly bacteria and certain cancers in a patient’s exhaled breath. One of the devices under development at the company is a device intended to detect lung cancer – and there has been quite a bit of activity surrounding the device’s development lately.

In November, Zenosense announced plans to manufacture a pre-market prototype device that would ultimately be evaluated during a lung cancer detection trial in a clinical setting. Zenon Biosystem, Zenosense’s contracted development partner, took on the task of manufacturing the prototype. In preparation for the planned trial and to meet the standards of the trial’s protocol design, Zenon planned to manufacture two pre-commercial devices of identical design to ensure that trial results could be duplicated.

A month later, in December 2014, Zenon announced that it would be collaborating with a university and a large university hospital in Madrid, Spain on a nine month long lung cancer detection trial that will facilitate clinical tests on breath samples from 400 people; this is also in line with the protocol design that was previously announced.

The Zenosense team believes that a cost-effective, breath-analyzing lung cancer detector that is proven to meet or exceed the accuracy of low-dose Computed Tomography (CT) scanning will have broad appeal and demand. As a result, the team has eagerly welcomed the news that a group of university research scientists and the university hospital have recognized the potential for their technology. A positive outcome from the planned lung cancer detection trial will be a significant step toward a major healthcare breakthrough.

For more information, visit www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

Zenosense, Inc. (ZENO) Lung Cancer Detection Device Trials Could Lead to Commercial Bonanza in Diagnostics Market

January 12, 2015

Zenosense currently holds an exclusive global license agreement for the development and marketing of revolutionary sensor devices designed to detect the MRSA “Super-Bug” (Methicillin-resistant Staphylococcus aureus), as well as lung cancer, in the exhaled breath of patients via a proprietary fusion of technologies that can actually sniff out associated VOC (volatile organic compound) biomarkers. Currently, lung cancer is the leading cancer killer and results in some 1.6M deaths per year, or more than the next three most common types of cancer combined, according to World Health Organization statistics.

Until recently, a widely accepted screening technology for accurately detecting early-stage lung cancer has not been readily available (ultrasound and X-Rays are largely ineffective at catching tumors early). The low-dose computed tomography (LDCT) scans which have emerged are rather involved for the patient and the healthcare facility administering them, they carry the same or greater component risks as a typical CT scan (which can damage DNA and actually trigger tumor growth), they lack robust specificity (high false-positive rate), and LDCT scans typically run somewhere in the ballpark of $500 a pop. Moreover, in lung cancer cases, as is the case with MRSA infections, early detection is key (making cumbersome or costly testing methods untenable for many) not only for survival rates and delimiting damage to the patient’s body, but for curbing the systemic cost impact to the healthcare system as well.

The global market for drugs alone to treat NSCLC (non-small-cell lung cancer), the most common type of lung cancer, accounting for around 90% of all cases, is on track to hit $6.9B by 2019, led by companies like AstraZeneca (NYSE: AZN), Roche (OTCM: RHHBY), and Merck (NYSE: MRK). In fact, the overall treatment market is estimated as growing at a CAGR of roughly 4.84% over the same interval, with yet-emerging markets like India seeing a much higher CAGR of around 13.47% through 2015, according to a GBI Research report which was published in September of 2014 by Transparency Market Research.

Looking at the sprawling global cancer diagnostics market, lung cancer accounted for the largest share of the space last year and is estimated as continuing to grow alongside cancer runaway incident rates, steadily rising for the foreseeable future. Hence the significance to investors of a device like the one being developed by Zenosense (OTCQB: ZENO), under an agreement with European sensor developer Sgenia Group, via Sgenia’s Zenon Biosystem subsidiary. Estimated manufacturing costs for the device(s) of only $100, or possibly as little as half that sum, due to incredible advances made by Sgenia/Zenon in the field of sensor engineering technologies, promises to bring to market an affordable, highly-accurate system for early detection of both deadly bacteria and certain cancers.

Utilizing established Sgenia programming and patent-pending hardware, the devices create tens of thousands of “virtual sensors” off of a single physical sensor, allowing for a nearly infinite number of scans to be rapidly performed. Designed to simply be worn by patients and/or be placed in sensitive areas in primary healthcare settings, the lung cancer detection device continuously monitors patient headspace for exhaled breath, which is then screened for the relevant biomarkers. An ingenious fusion of biochemistry, microbiology, molecular biology, nanotechnology, polymer electrochemistry and sensor engineering with high-level mathematics, the company’s devices may hold the key to saving countless lives through early detection and, in the case of healthcare acquired infections (HAIs) like MRSA alone, as much as $31.5B a year in medical costs inside the U.S. (CDC data).

As of November 2014 the company had reported manufacturing of a pre-commercial prototype lung cancer detection device and subsequently announced in December that Zenon had entered into a collaboration agreement to run a 400-patient trial with a university and large university hospital in Madrid. Given the relative treatability of lung cancer when it is still in Stage 1, the success of a non-invasive and cost-effective screening device like this, which could be ubiquitously disseminated throughout the healthcare system, could lead to the device becoming an industry standard, as well as huge revenue streams for ZENO.

For more information, visit www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

Zenosense, Inc. (ZENO) Technologies to Address Key Public Health Concerns

January 5, 2015

Zenosense is primarily focused on addressing unmet medical needs pertaining to bacterial infections and cancer. Leveraging a collaboration agreement with Sgenia Group subsidiary Zenon Biosystem, Zenosense is developing and plans to market two early detection devices, one for Methicillin-resistant Staphylococcus aureus (MRSA) and one for lung cancer.

MRSA-infected patients are likely to spend three times as long in a hospital, costing the United States’ healthcare system approximately $3.2 billion to $4.2 billion annually. MRSA-infected patients are also five times more likely to die than an uninfected patient, which further emphasizes the drastic need for early detection of hospital acquired infections (HAIs) such as MRSA. Though studies suggest that prevention practices have the potential to slash certain HAIs by up to 70%, there is currently no cost effective early detection device on the market.

Zenon Biosystem recently entered into a collaboration agreement with a university and large university hospital in Madrid, Spain, for a lung cancer detection trial involving breath samples from 400 people. The nine-month trial aims to identify VOCs in exhaled breath using standard lab instruments and techniques alongside two identical pre-commercial lung cancer devices that have been developed by Zenon to determine the relative efficacy of Zenon’s devices.

The Zenosense detection devices utilize a common electronic nose technology platform that analyzes volatile organic compounds (VOCs) found in the exhaled breath of patients and scans for certain biomarkers that indicate the presence of infection or illness before a patient demonstrates any obvious symptoms. The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals as well as placed in numerous sensitive areas in the healthcare setting.

Once developed, Zenosense’s cost-effective detection devices are expected to cater to a large, high-demand market driven by patient safety, cost and insurance considerations.

For more information, visit www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

Zenosense, Inc. (ZENO) Sensing Growth in 2 Vital Detection Markets

December 22, 2014

In modern medicine, life and death can be measured in mere days or weeks. Early detection of various cancers and illnesses can often mean a huge difference in survival rates of patients. You may often hear some doctors say that “if you had come in to see me a week later, it might have been too late,” or “if you had come in two weeks sooner, we would have never seen that growth.”

Medical technology has been continuing to evolve to find ways for certain cancers and illnesses to be spotted before a patient enters a doctor’s office for a routine exam. Zenosense, Inc. (OTCQB: ZENO) is one of the one-and-coming early-detection players, and continues to progress toward using exhaled breath as a tool for detection of possible infection or disease.

Zenosense is currently working a couple of devices that will help people use exhaled breath to indicate the presence of MRSA or lung cancer. Research as shown evidence of what are called “markers” that could be found in a person’s exhalations that may suggest the presence of either one of these disorders – potentially sooner than could be found in regular hospital tests. The company recently announced plans to develop a prototype electronic nose device that would be designed to detect lung-cancer markers. The prototype would soon be subject to a clinical trial.

With lung cancer being one of the more common forms of cancer, and with MRSA being very dangerous and deadly due to its antibiotic resistance and propagating ability, any company that is focusing on early detection of either of these illnesses is a company to which one should pay attention. If Zenosense can successfully develop a prototype early-detection device for either or both of these conditions, medicine could be disrupted in ways from which it may never recover. But that can be a strong lead toward establishing better health among patients and fewer hospital visits.

For more information, visit www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

Zenosense, Inc. (ZENO) Early Detection Systems for MRSA/SA & Lung Cancer Proactively Address Massive Global Market

December 12, 2014

In the case of most progressive illnesses, early detection is key, and this is particularly true for both primary types of lung cancer, NSCLC and SCLC (non-small cell lung cancer and small cell lung cancer), as well as the “Super Bug” known as MRSA (Methicillin-resistant Staphylococcus aureus). MRSA, a kind of robust and highly persistent staph bacterium, is a major, growing concern for hospitals, due in large part to this nasty little bug’s ability to shrug off the most powerful antibiotics available today. Whether a given infection is technically classified as a CA-MRSA (community-acquired) or HA-MRSA (hospital-acquired), the patient end point is invariably a healthcare facility, where the bug may spread and/or lie dormant, posing a serious propagation threat, both for patients and healthcare professionals alike.

Surgical site infection (SSI) continues to be one of the most dangerous postoperative complications, accounting for roughly one third of all HAI’s (hospital-acquired infections) and of that approximately 33% of all HAI’s, nearly 30% are MRSA-positive. MRSA loves to live in the skin and is often hiding in places like the nose, throat and armpits of carriers, making successful decolonization of a given subject extremely tricky. Decolonization requires prolonged treatments, like 5 to 10 days of twice-daily mupirocin in the nose, oral rinsing with 0.2% chlorhexidine three times a day for a week to try and clear the throat, or dilute bleach baths for as long as three months in order to decontaminate carriage sites on the body.

The global HAI testing market ran about $2.2B just two years prior and was recent forecast by Transparency Market Research as topping out around $7.5B in 2019, on a CAGR of roughly 19.3%, making this a huge target for developers and an area of considerable interest for investors as well. The ability to test early and actually prevent more serious/costly issues is an extremely attractive approach for curbing the soaring overall healthcare cost impacts to various economies, making the emergence of detection devices a highly sought-after possibility.

NSCLC lung cancer accounts for as much as 90% of all cases and the global market for just drugs to treat such cancer is on-track to hit around $6.9B by 2019 on a 4.84% CAGR, with the broader therapy market being much larger and on-track to hit around $7.9B by 2020 (GBI Research). With a projected CAGR somewhere in the neighborhood of 6.6%, as new drugs and premium therapies, like second-line and squamous cell treatment continue to emerge and offset generic chemotherapies, the NSCLC treatment market is growing just as fast as a malignant cancer itself. The biggest players like AstraZeneca (NYSE:AZN), Roche (OTCQX: RHHBY) and Merck (NYSE: MRK) will continue to drive the trend towards market segmentation in lung cancer treatment with premium therapies and new drugs, according to GBI Research.

The recent announcement by Zenosense, Inc. (OTCQB: ZENO), which is currently developing two types of electronic nose devices via contract with Zenon Biosystem that continuously monitor for and accurately discriminate hallmark VOCs (volatile organic compounds) of key MRSA and lung cancer biomarkers, that their common stock has been approved by the DTC (Depository Trust Corporation) for DWAC/FAST transfer, makes this small sector up-and-comer even more attractive as a vehicle for investors to tap into these markets. As a developer of detection devices that could save lives while grabbing market share from the treatment end of the game, ZENO’s technology is disruptive and could change the entire MRSA/SA and lung cancer markets on a fundamental level. DWAC/FAST transfer approval of the company’s common stock, using ZENO’s transfer agent, Action Stock Transfer Corporation, confers considerable benefits to shareholders as well. Including rapid brokerage account deposits and withdrawals, elimination of risk associated with handling physical certificates, and the higher liquidity that comes along with such enhanced share accessibility/availability.

Zenosense announced manufacturing of their pre-commercial prototype lung cancer detector early last month (November 4), highlighting key features like the device’s ability to rapidly discriminate against background VOCs in the breath of patients and hone in on the target lung cancer VOC biomarkers. Development partner Zenon Biosystem has come up with some cunning adaptations of the detection pipeline, using molecular sieves in complementary layered and mixed sensor structures, and has developed new metal oxide materials and combinations of metal oxides not found anywhere in the commercially available sensor market today.

Similar breakthroughs in the development of the company’s MRSA detector, including novel biomarker micro-separator sensor technology, has led to testing of a prototype to measure and contrast cultures of MRSA and SA, with a subsequent announcement in late October that the device successfully achieved a sensibility detection rate on cultured headspace in a clinical setting of over 95% during a two-week testing period. The considerable progress ZENO has made in a relatively short time towards commercialization of such highly accurate early detection devices for lung cancer and MRSA/SA could potentially revolutionize the approach to both maladies and saves countless lives.

Given the 224k or so new cases of lung cancer in the U.S. alone each year (around 160k deaths, American Cancer Society) and CDC’s best estimates that 33% of Americans are staph carriers, with 10.8k deaths in the each year from staph, 5.5k of which are MRSA related, there is a massive target market for ZENO’s detection systems.

For more information on Zenosense, please visit: www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

Zenosense, Inc. (ZENO) Moves Forward with Manufacturing Pre-Market Lung Cancer Detection Device

December 3, 2014

Zenosense is a company on a mission. The emerging healthcare technology company has undertaken the challenge of developing functioning yet cost-effective medical devices that will detect, early on, deadly bacteria and certain cancers in a patient’s exhaled breath.

The company currently has two devices under development:

• a device intended to detect lung cancer

• a device intended to detect the Methicillin-resistant Staphylococcus aureus “Super-Bug” (MRSA)

The process of developing the lung cancer detection device has been interesting lately. This past November, Zenosense revealed plans to manufacture a pre-market prototype device that will eventually be evaluated during a lung cancer detection trial in a clinical setting.

Zenon Biosystem, Zenosense’s contracted development partner and a member company of the Sgenia Group, has undertaken the task of manufacturing the prototype. In preparation for the expected lung cancer detection trial and in accordance with the protocol design for the trial, Zenon will manufacture two pre-commercial devices of identical design to ensure that trial results can be replicated.

The device will be designed using an Electronic Nose technology platform. It will incorporate components capable of filtering out Volatile Organic Compounds (VOCs) that are not of interest in order to improve the detection of specific VOC biomarkers found in exhaled breath and linked to the incidence of lung cancer. In keeping with its mission, Zenosense means to use components of a relatively low cost to create this product cost-effectively.

Zenon is hard at work establishing the necessary collaborations needed to carry out the planned lung cancer detection trial, and Zenosense is eagerly anticipating the testing of the prototype in the trial. Zenosense believes a cost-effective, breath-analyzing lung cancer detector that is proven to meet or, better yet, exceed the accuracy of low-dose Computed Tomography (CT) scanning will generate wide appeal and, subsequently, substantial demand.

For more information, visit the company’s website at www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

How Zenosense, Inc. (ZENO) Aims to Revolutionize Lung Cancer Detection

November 25, 2014

More Americans die from lung cancer than any other type of cancer. The CDC reports that in 2011, out of the 207,339 Americans diagnosed with lung cancer, 156,953 people died from the disease. Science is advancing screen cancer screening technology, though current methods unarguably have room for improvement.

Mortality rates were reduced by 20% in patients that underwent screening with low-dose computed tomography (CT) compared to radiographic screening, according to the National Institutes of Health. Despite the effectiveness and benefits of CT screening, this method carries a higher risk of false-positive results and unnecessary invasive procedures compared to X-ray screening, though the latter method is no longer recommended for screening.

Healthcare technology innovator Zenosense is developing an alternative that the company believes has the potential to meet or exceed the accuracy of CT scanning without risk and at a lower cost. Zenosense’s development partner, Zenon Biosystem (“Zenon”), is currently manufacturing two pre-commercial prototypes of a screening device that analyzes a person’s breath to detect lung cancer.

Here’s why it could work. Numerous scientific studies suggest that lung cancer alters cellular metabolism, resulting in the production of a number of distinctive Volatile Organic Compounds (VOCs) in exhaled breath. Zenosense’s device filters out VOCs NOT of interest to optimize the detection of target VOC biomarkers that are associated with the incidence of lung cancer.

When manufacturing is complete, Zenosense plans to conduct a lung cancer detection trial to be carried out in a clinical setting using two of the devices of the same design to ensure reproducibility of results. Clinical tests will examine 400 subjects split into four groups to include smokers, non-smokers, and those suffering from lung cancer and chronic obstructive pulmonary disease (COPD).

A preliminary commercial target for Zenosense will be to establish whether its device can meet or exceed the accuracy of low-dose CT scanning to detect early stage lung cancer, which currently is the only realistic method for mass screening. The company anticipates completing its manufacturing later this month.

For more information, visit www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

Zenosense, Inc. (ZENO) Steadily Progressing Toward Commercialization of a Low Cost, Rapid Detection Device for Both MRSA & Lung Cancer

November 19, 2014

Zenosense has posted some solid news in the last two months on the progress of their rapid detection sensor technology for sniffing out MRSA/SA Super-Bug (Methicillin-resistant Staphylococcus aureus) and lung cancer from patient’s breath. Devices whose advent could create a paradigm shift in currently costly, time-consuming and/or dangerous testing methodologies.

Late last month, the company was proud to report that their MRSA/SA detector prototype successfully scored a 95% plus detection rate in clinical testing, with key circuit board integration advancement also occurring, including a powerful solid-state processor and low power piezoelectric (electric charge created through applied mechanical stress on certain types of material) sampling pump. Ongoing development of the company’s core technology has led to a simple, yet effective design, which neatly encapsulates all the hardware and circuitry, and yet is able to run continuously for an entire standard shift thanks to the device’s low power consumption profile, while still incorporating a four sensor parallel array. The MRSA/SA detector prototype does continuous sampling at a rate of once every handful of milliseconds, rapidly testing cultured patient headspace for key VOC (volatile organic compound) indicators, using a sophisticated architecture that spans air injection capable of sampling a negative vacuum, suction, data download, and a self-cleaning cycle.

Such a device is a quantum leap beyond collecting swab samples and sending them off to the lab for testing, a process which can take considerable time and money. Even advanced PCR-based (polymerase chain reaction) rapid testing still requires swabbing and sequencing. A logistically inefficient approach considering that, despite seeming declines from 2005 CDC/JAMA figures of around 95k infections and over 18k related MRSA fatalities, antibiotic resistant MRSA infection led to more deaths in the U.S. alone than emphysema, HIV/AIDS, Parkinson’s disease, and homicides combined in recent years. Despite the latest studies indicating invasive MRSA infection and fatality rates have declined to around 80k and 11k respectively or less, patients are twice as likely to die when they have MRSA, compared to methicillin-treatable Staph, with hospitalized MRSA patients costing the healthcare system as much as $4.2B a year according to an Issue Brief from the Pew Charitable Trust.

Indeed, broader hospital-acquired infection (HAI) prevalence and its results, as reported by Kaiser Health News, indicate the true need for a rapid detection device. As many as 1 in every 25 hospital patients were found to have acquired some kind of infection according to the Kaiser study, resulting in over 75k deaths each year. A growing elderly population of rapidly retiring Baby Boomers, with almost 11k per day becoming eligible for retirement, are particularly at risk given the sizeable number who are increasingly on some form of immune-suppressing drug for conditions like alopecia, arthritis, Crohn’s disease, M.S., psoriasis, or a recent transplant.

ZENO’s work on applying their detection technology to lung cancer has also seen some nice traction in October and November of this year, with the latest report out earlier this month indicating that the company is already in advanced pre-commercial prototyping on their lung cancer detector. The device, being developed via Sgenia group company and ZENO partner, Zenon Biosystem, even has advanced filtering technology that is specifically designed to target and screen out VOC biomarkers not associated with lung cancer. Subsystem optimization, including filtering technology using molecular sieves built right into the layered/mixed sensor array, as well as a nanometric sensing mesh to ensure a maximum detection footprint, has gone quite well, leading to high confidence at ZENO that these low cost components will nevertheless achieve top line results in the final device design.

Zenon has even made some serious breakthroughs with novel metal oxide sensor materials not currently commercially available anywhere else and the incorporation of a micro gas chromatography chip, as well as quartz crystal sensor with gas sorbent substrate, means the lung cancer detection device will likely provide some of the best pre-detection screening, as well as highly-accurate lung cancer-associated VOC sensing possible. Two identical pre-commercial detection devices are either being manufactured or have already been completed as of the time of this writing, according to the given timeline estimates. This places ZENO squarely on-track for subsequent clinical testing and the company is currently gearing up for a planned lung cancer detection trial in cooperation with Zenon. ZENO could bring an extremely cost-competitive alternative to the lung cancer detection market, offering a compelling new choice over the industry standard, “low-dose” CT scanning, which actually increases the risk of cancer, using around 150 to 1.1k times the radiation of a typical x-ray.

Lung cancer is the number one cancer killer in the U.S. for both men and women, resulting in more deaths than the next three most common cancers combined (breast, colon and pancreatic), and is even more prevalent in women than breast cancer. ACA data even indicates that among the 108k new cases of lung cancer in women diagnosed each year, a staggering 66% plus will perish, throwing a bright spotlight on the underlying demand curve for the emergence of a rapid detection system like the one Zenosense has under development.

For more information on Zenosense, visit: www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

Zenosense, Inc. (ZENO) Pursues Super-Bug Device Development

November 10, 2014

Zenosense is focused on emerging technology. From the start, the healthcare technology company has sought to develop an operational Super-Bug or Methicillin-resistant Staphylococcus aureus (MRSA) detector for use in hospitals, clinical environments and other healthcare settings.

Last year, Zenosense outsourced the development of its device to The Sgenia Group, a well-known sensor developer. Sgenia intends to model the new device after the algal (water) sensor platform it developed and to use a solo, commercial “off-the-shelf” gas sensor to sample the air and continuously check for the airborne Volatile Organic Compounds signature emitted by MRSA/SA. The device development process is intended to be completed in three distinct phases:

• Phase 1

The first phase will be to produce a prototype that leverages Sgenia’s technology and successfully detects MRSA/SA contamination. Significant engineering work will be needed to adjust and adapt existing sensor capabilities to the planned application. The modification of algorithms will also be required to conform to MRSA/SA bacteria analysis. All of these developments will most likely be protected as industrial secrets rather than patents.

• Phase 2

The second phase will be to build prototypes as well as conduct lab tests with a minimum of 20 beta versions of the MRSA/SA detection device. Next, a pre-production design appropriate for hospital use will have to be delivered. A vital aspect of this phase will be authenticating the device and achieving accuracy and repeatability. Testing will include: addressing the contaminating influences of environmental conditions, like humidity, temperature and other gasses, as well as the interference from other families of bacteria; and achieving the standard and quality levels required for hospital use.

• Phase 3

The third and final phase will be to obtain pertinent regulatory approvals in the United States and European Union and to produce a final product ready for mass production and marketing. Steps during this phase will include: final testing by an external and specialist laboratory of microbiology; preparing and pursuing applications for approval; remedying any problems detected during testing; as well as preparing for mass production of the device, once all relevant tests and approvals are obtained.

The development of the Zenosense device started in December 2013. Months later, in late October 2014, Zenosense announced that major progress had been made in the development of its MRSA/SA detector. The prototype device successfully achieved a sensibility detection rate greater than 95% on cultured headspace in a sequence of tests over a two-week period in a clinical setting. The general development of the device technology, which will detect the MRSA Super-Bug, was also proceeding in line with the company’s expectations.

For more information, visit www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

Zenosense, Inc. (ZENO) Pre-Commercial Lung Cancer Detection Device Manufacturing Underway

November 4, 2014

Zenosense, a healthcare technology company principally engaged in developing and marketing devices to detect the MRSA “Super-Bug” and to detect signs of lung cancer in exhaled breath, announced it has manufactured a pre-commercial prototype device. The device is expected to be evaluated for the detection of lung cancer in exhaled breath.

The work involved in the prototyping process has been entrusted to the company’s contracted development partner Zenon Biosystem (“Zenon”), a component of the Sgenia group. In line with the protocol design for an anticipated lung cancer detection trial, two pre-commercial devices are currently being manufactured with the identical design, thereby ensuring the results are reproduced. The devices are expected to be ready later this month.

The device uses components that remove irrelevant Volatile Organic Compounds (“VOCs”) in order to optimize the detection of target VOC biomarkers found in exhaled breath and connected with the incidence of lung cancer. These components include molecular sieves used in complementary layered and mixed sensor structures to screen incoming VOCs, and nanometric sensing mesh to maximize the detective area.

ZENO is eagerly anticipates testing of the devices in the planned lung cancer detection trial while work at Zenon is ongoing to establish the necessary outcomes to carry out the trial. The company believes that a cost-effective lung cancer detector analyzing exhaled breath proven meets or exceeds the accuracy of low dose CT scanning will have wide appeal and subsequently satisfy demand.

Zenosense, Inc., a detection device development company, outlays a mission to develop effective medical devices targeting early detection of both deadly bacteria and certain cancers in the exhaled breath of patients. Ultimately, the company intends to sell these products to primary healthcare facilities and hospitals. A device intended to detect the Methicillin-resistant Staphylococcus aureus MRSA and a device intended to detect Lung Cancer are currently under development.

For more information on the company, visit www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

Zenosense, Inc. (ZENO) MRSA/SA Prototype Device Achieves Sensibility Detection Rate Over 95%

October 28, 2014

Zenosense, a healthcare technology company with a focus on developing and marketing devices to detect the MRSA “Super-Bug” and to detect signs of lung cancer in exhaled breath, has announced considerable progress in its MRSA/SA detector development. It has been determined that the prototype device achieved a sensibility detection rate over 95% on cultured headspace in a series of tests over a two week period in a clinical setting.

In other developments, the company’s general device technology development designed to detect the Methicillin-resistant Staphylococcus aureus “Super-Bug” (“MRSA”), non-resistant “Staph” (“SA”), is also moving forward in line with ZENO expectations.

Electronic improvements have resulted in printed circuit board prototyping that includes integration of a powerful solid state processor, a suitable, low power, piezo electric sampling pump, a capability to run up to four sensors of different technologies working in parallel on a tens of milliseconds sampling frequency, to include measuring and cleaning time and low power consumption enabling an extended operating time on battery power to cover at least one normal working shift when operating continuously.

A Volatile Organic Compound (“VOC”) capturing system, which enables the prototyped device to sample cultured headspace, has also been developed. The system includes an air injection system to enable the device to sample a negative vacuum, a suction process, data download and a cleaning cycle.

Pending developmental activity includes Quartz Crystal Microbalance sensor testing, sensitivity testing against VOC biomarkers, assessment of accuracy and repeatability, and a review of temperature sensitivity, humidity and gas interference factors.

Zenosense is a detection device development company with a mission to develop effective medical devices targeting the early detection of both deadly bacteria and certain cancers in the exhaled breath of patients. Its goal is to sell these products to hospitals and primary healthcare facilities. Devices currently under development are a device intended to detect the Methicillin-resistant Staphylococcus aureus (MRSA) and a device intended to detect Lung Cancer. Using a common Electronic Nose technology platform, the devices analyze Volatile Organic Compounds (VOCs) which are present in the exhaled breath of patients.

Find out more at www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

Zenosense, Inc. (ZENO) Completes Protocol Design – Lung Cancer Detection Trial on Deck

October 22, 2014

Zenosense, a healthcare technology company involved in developing and marketing devices to detect MRSA and signs of lung cancer in exhaled breath, has announced the completion of protocol design of a significant lung cancer detection trial. Testing will done in a clinical setting and is subject to agreements with a compatible hospital in the near future.

The aim of the trial is to test the ability of a prototype Zenosense lung cancer detector, currently under development. Clinical tests will divide a total of 400 patients into four groups; smokers, non-smokers, lung cancer patients and those diagnosed with Chronic Obstructive Pulmonary Disease.

There is extensive scientific data which indicates that lung cancer causes alterations in cellular metabolism, due to oxidative stress, resulting in the production of a number of distinctive Volatile Organic Compounds in exhaled breath. The trial looks to identify the lung cancer biomarkers and to determine the adequacy of the Device in detecting these biomarkers, compared to conventional laboratory analysis.

Breath samples will be taken from each subject using a standard breath sampler. They will be captured, stored and analyzed to a strict protocol taking into account ambient air samples. These samples will be analyzed in parallel by conventional laboratory methods including Gas Chromatography (“GC”) and Mass Spectrometry (“MS”); and by two prototype devices of the same design, to ensure device results are copied.

Zenosense is a detection device development company based in Valencia, Spain. ZENO endeavors to develop medical devices targeting the early detection of both deadly bacteria and certain cancers in the exhaled breath of patients. Further, the company looks to market and sell these products to hospitals and primary healthcare facilities. The two devices currently under development are a device intended to detect the Methicillin-resistant Staphylococcus aureus “Super-Bug” (MRSA) and a device intended to detect Lung Cancer. Using a common Electronic Nose technology platform, the devices analyze Volatile Organic Compounds (VOCs), which are present in the exhaled breath of patients, scanning for certain biomarkers which can indicate the presence of infection/illness.

For more information on the company, visit www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

Archives

Select A Month
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Search

    Categories

    Select A Category
  • 21st Century Holding Company TCHC (1)
  • 5BARz International Inc. BARZ (12)
  • 5G Wireless Communications Inc. FGWC (8)
  • 92 Resources Corp. RGDCF (6)
  • A.P. Pharma Inc. APPA (3)
  • Abazias Inc. ABZA (2)
  • ABcann Global Corp. ABCCF (14)
  • ABV Gold ABVG (11)
  • ACME Sports & Entertainment Inc. ASEN (2)
  • Adaptive Medias Inc. ADTM (6)
  • Advanced ID Corp. AIDO (5)
  • Advanced Medical Isotope Corp. ADMD (10)
  • Advanced Resources Group Ltd. AVRG (3)
  • Advanced Viral Research Corp. ADVR (9)
  • Advanced Visual Systems Inc. AVSC (10)
  • Advanced Voice Recognition Systems Inc. AVOI (11)
  • Advanced Wound Technologies Inc. AWTM (4)
  • Advaxis Inc. ADXS (2)
  • Agora Holdings Inc. AGHI (33)
  • Ahead of the Bulls (1)
  • AISystems, Inc. ASYI (11)
  • Aladdin Trading & Company ADTD (29)
  • Algae Dynamics Corp. ADYNF (28)
  • All American Gold Corp AAGC (13)
  • All Asia Licensing Inc. AASI (1)
  • ALL Fuels & Energy Company AFSE (49)
  • All Grade Mining Inc. HYII (3)
  • All Penny Stocks (3)
  • Allarae Healthcare Inc. ALHI (5)
  • Alliance Creative Group ACGX) (15)
  • Alliance Recovery Corp. ARVY (34)
  • Alltemp, Inc. LTMP (1)
  • AlphaTrade.com APTD (2)
  • Alpine TLI Group Inc. APGR (7)
  • ALR Technologies Inc. ALRT (9)
  • Alternative Construction Technologies Inc. ACCY (10)
  • Alternative Energy Development Corp. ADEC (1)
  • Alternative Fuel Technology Inc. AFTC (1)
  • Alternet Systems Inc. ALYI (47)
  • AM Oil Resources & Technology Inc. AMOR (8)
  • Amarin Corp. AMRN (2)
  • Amaru Inc. AMRU (2)
  • Amerex Group, Inc AEXG (16)
  • American Capital Partners Inc. APRJ (1)
  • American Fiber Green Products Inc. AFBG (1)
  • American Oriental Bioengineering Inc. AOB (3)
  • American Racing Capital Inc. AMRA (2)
  • American Software (2)
  • Amgen Inc. AMGN (2)
  • AmMex Gold Mining Corp. AMXG (2)
  • Ampex Corp AMPX (1)
  • Andover Medical Inc. ADOV (2)
  • Angstrom Microsystems Inc. AGMS (46)
  • Apolo Gold and Energy Inc. APLL (1)
  • Apple Inc. AAPL (13)
  • AppSwarm, Inc. SWRM (17)
  • Aquasil International Inc. AQUS (3)
  • Armco Metals Holdings Inc. AMCO (36)
  • AspenBio Pharma APPY (1)
  • Assured Pharmacy Inc. APHY (1)
  • Asta Funding Inc. ASFI (2)
  • Atlantic Energy Solutions Inc. AESO (1)
  • ATSI Communications Inc. ATSX (1)
  • Augme Technologies Inc. AUGT (70)
  • Auric Mining Corp. AUMY (3)
  • Automated Vending Technologies Inc. AVTC (3)
  • Automotive Company GNAU (11)
  • Avalon Oil and Gas Inc. AOGN (16)
  • Avant Diagnostics Inc. AVDX (29)
  • Avatar Systems Inc. AVSY (3)
  • Axiom Management Inc. AXMA (3)
  • Axis Technologies Inc. AXTG (2)
  • B2Digital Inc. BTOD (18)
  • Balatia Airlines BLTA (2)
  • Bald Eagle Energy Inc. BEEI (18)
  • Banjo & Matilda Inc. BANJ (8)
  • Barchart.com (4)
  • Beacon Enterprise Solutions Group BEAC (47)
  • Beacon Equity Research (552)
  • Beijing Med-Pharm Corp. BGJP (2)
  • Bergamo Acquisition Corp. BGMO (15)
  • Big Tree Group Inc. BIGG (36)
  • Bio-Clean International Inc. BCLE (1)
  • Bio-Matrix Scientific Group Inc. BMSN (1)
  • BioCentric Energy Holdings Inc. BEHL (1)
  • Biomagnetics Diagnostics Corp. BMGP (3)
  • bioMETRX Inc. BMRX (1)
  • Bionic Products Corp. BNPD (4)
  • Biophan Technologies Inc. BIPH (1)
  • BioSolar Inc. BSRC (22)
  • Biotech Holdings Ltd. BIOHF (3)
  • BizRocket.com Inc. BZRT (9)
  • Black Diamond Brands Corp. BDMHF (1)
  • Blue Diamond Ventures Inc. BLDV (1)
  • Blue Moon Zinc Corp. BMOOF (3)
  • Blue Water Global Group Inc. BLUU (7)
  • Blugrass Energy Inc. BLUG (4)
  • Bollente Companies, Inc. BOLC (7)
  • BoonMarket.com (1)
  • Boreal Water Collection Inc. BRWC (23)
  • Boston Therapeutics Inc. BTHE (20)
  • Bridgetech Holdings International Inc. BGTH (1)
  • Brighton Oil & Gas Inc. BROG (8)
  • Britannia Mining Inc. BMIN (14)
  • Brite Strike Tactical Illumination Products, Inc. BSTI (41)
  • Brookside Technology Holdings Corp BKSD (2)
  • Bullzi Security Inc. BLLZ (3)
  • BWI Holdings Inc. BWIH (165)
  • Cache Elite Inc. ILUS (2)
  • Cal-Bay International Inc. CBYI (6)
  • Callisto Pharmaceuticals, Inc. (1)
  • Calpian Inc. CLPI (27)
  • CAMAC Energy Inc. CAK (2)
  • Canam Energy Inc. CNGJ (10)
  • CanAm Uranium Corp. CAUI (58)
  • Cannabics Pharmaceuticals Inc. CNBX (14)
  • Capital City Energy Group Inc. CETG (18)
  • Car Monkeys Group CKMY (15)
  • Carbon Sciences Inc. CABN (21)
  • CardioVascular BioTherapeutics Inc. CVBT (5)
  • Cardium Therapeutics Inc. CXM (44)
  • Cascade Technologies Inc. CSDT (2)
  • Cascadia Investment Inc. CDIN (4)
  • Casey Corp. CCPR (1)
  • Cashcow Magazine (4)
  • Cavico Corp. CVIC (3)
  • CD International Enterprises, Inc. CDII (48)
  • CDC Corp. CHINA (4)
  • CelebDirect Inc. CELI (3)
  • Cellceutix Corp. CTIX (18)
  • CellCyte Genetics Corp. CCYG (3)
  • Century Group, Inc. CEYG (1)
  • CEOcast (184)
  • CepTor Corp. CEPO (1)
  • Cereplast Inc. CERP (9)
  • Chancery Resources Inc. CCRY (3)
  • Changing Times Vitamins Inc. SGTB (12)
  • CHDT Corp. CHDO (5)
  • Cherubim Interests Inc. CHIT (36)
  • China 3C Group CHCG (13)
  • China America Holdings Inc. CAAH (8)
  • China Direct Inc. CDS (4)
  • China Education Alliance Inc. CEUA (4)
  • China Energy Recovery Inc. CGYV (12)
  • China Growth Development Inc. CGDI (2)
  • China Health Management Corp CNHC (7)
  • China Health Resource Inc. CHRI (14)
  • China INSOnline Corp. CHIO (1)
  • China Jiangsu Golden Horse Steel Ball Inc. CJGH (3)
  • China Logistics Group Inc. CHLO (11)
  • China Media Group Corp. CHMD (2)
  • China Medicine Corporation CHME (5)
  • China Nuvo Solar Energy Inc. CNUV (3)
  • China Organic Agriculture Inc. CNOA (11)
  • China Petroleum and Chemical Corp. SNP (2)
  • China Voice Holding Corp. CHVC (47)
  • China Wind Systems Inc. CWSI (6)
  • China Wireless Communications Inc. CWLC (4)
  • China Yongxin Pharmaceuticals Inc. CYXN (5)
  • China YouTV Corp. CYTV (1)
  • ChinaTel Group Inc. CHTL (1)
  • Chineseinvestors.com, Inc. CIIX (65)
  • ChromaDex Corp. CDXC (3)
  • City Capital Corp. CTCC (2)
  • Cityside Tickets CIST (21)
  • CleanTech BioFuels Inc. CLTH (10)
  • Cleantech Transit Inc. CLNO (3)
  • Clearly Canadian Beverage Corp. CCBEF (13)
  • Cleartronic Inc. CLRI (52)
  • Clenergen Corp. CRGE (37)
  • CMG Holdings Inc. CMGO (2)
  • Coastal Integrated Services Inc. COLV (13)
  • Coil Tubing Technology Inc. CTBG (1)
  • Colorado Goldfields Inc. CGFI (5)
  • Colt Resources Inc. COLTF (13)
  • Columbia River Resources Inc. CRVR (1)
  • CoMedia Corp. CMTN (1)
  • CommercePlanet Inc. CPNE (4)
  • Compress Technologies Inc. CTLG (17)
  • Conforce International Inc. CFRI (2)
  • Connect-A-Jet.com CAJT (9)
  • Cono Italiano Inc. CNOZ (12)
  • Consorteum Holdings, Inc. CSRH (160)
  • ContentChecked Holdings Inc. CNCK (60)
  • Continental Fuels Inc. CFUL (2)
  • Converde Energy USA Inc. XFUL (12)
  • Convergence Technology Group Inc. CNVC (7)
  • Copper King Mining Corp. CPRK (2)
  • Cord Blood America Inc. CBAI (102)
  • Crdentia Corp CRDT (12)
  • Creative Vistas Inc. CVAS (2)
  • Crystal International Travel Group Inc. CINT (4)
  • Cubic Energy Inc. QBC (2)
  • Cybermesh International Corp. CYTL (1)
  • Cyclone Power Technologies Inc. CYPW (9)
  • CYIOS Corp. CYIO (1)
  • Daily Views (13)
  • Dakshidin Corp. DKSC (5)
  • Data Call Technologies Inc. DCLT (25)
  • Daulton Capital Corp. DUCP (26)
  • Davi Skin Inc. DAVN (1)
  • Debt Resolve Inc. DRV (2)
  • Debut Broadcasting Corporation Inc. DBTB (1)
  • Deep Blue Marine Inc. DPBM (6)
  • Deep Down Inc. DPDW (15)
  • Deer Valley Corp. DVLY (2)
  • Defense Solutions Inc. DFSH (3)
  • Delta Mining and Exploration Corp. DMXC (1)
  • Dermisonics Inc. DMSI (1)
  • Destination Television Inc. DSTV (17)
  • Dhanoa Minerals Ltd. DHNA (4)
  • DigitalPost Interactive Inc. DGLP (8)
  • Document Capture Technologies Inc. DCMT (3)
  • DoMark International Inc. DOMK (29)
  • Dominovas Energy Corp. DNRG (73)
  • Dragon Capital Group Corp. DRGV (11)
  • Dragon International Group Corp. DRGG (2)
  • Duma Energy Corp. DUMA (20)
  • Duska Therapeutics Inc. DSKA (1)
  • Dutton Associates (88)
  • DXP Enterprises Inc. DXPE (4)
  • Dynamic Media Holdings Inc. DYMH (6)
  • Dynamic Response Group Inc. DRGP (6)
  • Dynasty Limousine Inc. DNYS (19)
  • Earth Dragon Resources Inc. EARH (10)
  • Eastbridge Investment Group Corp. EBIG (1)
  • Ebenefits Direct, Inc. EBFD (21)
  • eCareer Holdings Inc. ECHI (9)
  • Echo Therapeutics Inc. ECTE (5)
  • EcoloCap Solutions Inc. ECOS (2)
  • Ecologic Transportation Inc. EGCT (11)
  • Ecosciences Inc. ECEZ (1)
  • Ecotality, Inc. ECTY (67)
  • eCrypt Technologies Inc. ECRY (79)
  • EdgeTech International Inc. EGIL (6)
  • eDoorways Corp. EDWY (183)
  • EFoodSafety.com Inc. EFSF (4)
  • EFuel EFN Corp. EFUL (1)
  • EGPI Firecreek Inc. EFIR (1)
  • Elephant Talk Communications Corp. ETAK (8)
  • Elephant Talk Communications Inc. ETAK (2)
  • Elleipsis Global Travel Solutions Inc. EGTS (3)
  • Elray Resources Inc. ELRA (11)
  • Elron Electronic Industries Ltd. ELRN (1)
  • Emerging Media Holdings Inc. EMDH (22)
  • Empire Energy Corporation International EEGC (3)
  • Endeavor Explorations Inc. EAVR (7)
  • Endeavour Silver Corp. EXK (3)
  • Endevco Inc. EDVC (2)
  • Energtek Inc. EGTK (61)
  • Enherent Corp. ENHT (2)
  • EnterConnect Inc. ECNI (5)
  • Enterprise Oilfield Group Inc. E.TO (13)
  • EnXnet Inc. EXNT (1)
  • Epazz, Inc. EPAZ (28)
  • Equity Stock Analysis (1)
  • ER Urgent Care Holdings Inc. ERUC (6)
  • ERF Wireless Inc. ERFB (15)
  • Essential Innovations Technology Corp. ESIV (2)
  • Etelcharge.com Inc. ETLC (3)
  • Ethema Health Corporation GRST (7)
  • Euoko Group Inc. EUOK (2)
  • EV Innovations Inc. EVII (189)
  • EV Transportation Inc. EVTP (7)
  • EVIO, Inc. EVIO (5)
  • Exchange Media Corp. EXMD (9)
  • Exeter Resource Corp. XRA (2)
  • eXp World Holdings, Inc. EXPI (81)
  • Expert Group Inc. EXPT (5)
  • ExpressIR Inc. (1)
  • Extreme Motorsports of California, Inc. EMOC (26)
  • ezBanc-A Stocklender's Journal (6)
  • Falcon Crest Energy FCEN (75)
  • Falcon Ridge Development Inc. FCNR (2)
  • Famous Uncle Als Hot Dogs & Grille Inc FDOG (10)
  • Fastfunds Financial Corp. FFFC (17)
  • Financial Media Group, Inc. FNGP (26)
  • Financial Services Exchange FSE (1)
  • First Titan Corp. FTTN (45)
  • FlexWeek Inc. FXWK (11)
  • FluoroPharma Medical Inc. FPMI (46)
  • Foldera, Inc. FDRA (11)
  • Force Energy Corp. FORC (5)
  • FormCap Corp. FRMC (29)
  • Fortune Market Media Inc. FTMM (5)
  • Franklin Mining Inc. FMNJ (1)
  • Freedom Leaf Inc. FRLF (12)
  • Fresh Harvest Products Inc. FRHV (7)
  • Fresh Promise Foods Inc. FPFI (12)
  • Freshstart Properties Inc. FSPP (1)
  • FrogAds Inc. FROG (6)
  • Frozen Food Gift Group Inc. FROZ (5)
  • Fund.com, Inc. FNDM (56)
  • Fushi Copperweld Inc. FSIN (2)
  • GainClients Inc. GCLT (9)
  • Galenfeha Inc. GLFH (28)
  • Gastar Exploration Ltd. GST (2)
  • Gemini Explorations Inc. GXPI (12)
  • Gen2media Corp. GTWO (2)
  • General Environmental Management Inc. GEVI (56)
  • General Metals Inc. GNMT (1)
  • General Steel Holdings Inc. GSI (3)
  • GeoBio Energy Inc. GBOE (1)
  • GeoEye Inc. GEOY (4)
  • GeoPharma Inc GORX (1)
  • Giggles N’ Hugs Inc. GIGL (90)
  • Global Alumina Corp. GLA.U (1)
  • Global General Technologies Inc. GLGT (1)
  • Global Payout Inc. GOHE (51)
  • Global Realty Development Corp. GRLY (10)
  • Global Resource Corporation GBRC (48)
  • Global Roaming Distribution Inc. GRDB (34)
  • GlobalWise Investments Inc. GWIV (129)
  • GNCC Capital Inc. GNCP (24)
  • Golden West Brewing Company Inc. GWBC (3)
  • GoldSpring Inc. GSPG (4)
  • Google, Inc. GOOG (8)
  • GotStocks.net (1)
  • Grandview Gold Inc. GVGDF (2)
  • Gray Publishing & Media, Inc. GPMIJ (15)
  • Graystone Park Enterprises Inc. GPKE (7)
  • Great Plains Holdings Inc. GTPH (28)
  • Green Earth Technologies GETG (1)
  • Green Star Alternative Energy Inc. GSAE (2)
  • Green Star Products Inc. GSPI (2)
  • Green Technology Solutions Inc. (GTSO) (19)
  • Greenbelt Resources Corp. GRCO (1)
  • Greenchek Technology Inc. GCHK (18)
  • Greenkraft, Inc. GKIT (9)
  • Greenstone Holdings Inc. GSHN (2)
  • GREM USA GRMU (2)
  • Grey Cloak Tech, Inc. GRCK (5)
  • GRILLiT Inc. GRLT (8)
  • Growblox Sciences Inc. GBLX (24)
  • GT Legend Automotive Holdings Inc. GTLA (2)
  • GTX Corp GTXO (49)
  • Gulf Western Petroleum Corp. GWPC (3)
  • GWS Technologies Inc. GWSC (4)
  • Halcyon Jets Holdings Inc. HJHO (15)
  • Halitron Inc. HAON (11)
  • Hanover Financial Services (17)
  • Harbin Electric Inc. HRBN (2)
  • Harvey Electronics Inc. HRVE (1)
  • Hasco Medical Inc. HASC (7)
  • Hathway Corp. HWYI (1)
  • HeadsUp Entertainment International Inc. HDUP (3)
  • Healthnostics Inc. HNSO (1)
  • HealthSonix Inc. HSXI (1)
  • HealthSport Inc. HSPO (14)
  • Heartland Inc. HTLG (1)
  • Heartland Oil and Gas Corp. HTOG (7)
  • Hemis Corporation HMSO (19)
  • Hemisphere Gold Inc. HPGI (1)
  • Hemp Inc. HEMP (25)
  • Hendrx Corp. HDRX (1)
  • Hi-Shear Technology Corp. HSR (3)
  • HighCom Global Security Inc. HCGS (13)
  • HII Technologies Inc. HIIT (8)
  • Holloman Energy Corp. HENC (2)
  • Holmes Osborne (6)
  • Hologic Inc. HOLX (4)
  • Home Shopping Latino Inc. HSPG (8)
  • Hong Kong Highpower Technology Inc. HPJ (2)
  • HotOTC (61)
  • HotStockChat (3)
  • HotStockMarket (HSM) (3)
  • HST Global Inc. HSTC (11)
  • Hunt Gold Corp. HGLC (32)
  • HWI Global Inc. HWIC (3)
  • Hydrogen Corp. HYDG (1)
  • i-Level Media Group Inc. ILVL (3)
  • i2 Telecom International Inc. ITUI (7)
  • iB3 Networks Inc. IBNW (1)
  • IceWEB Inc. IWEB (5)
  • ICP Solar Technologies Inc. ICPR (3)
  • IDGLOBAL Corp. IDGJ (2)
  • IDO Security Inc. IDOI (22)
  • IFAN Financial Inc. IFAN (34)
  • iGambit, Inc. IGMB (5)
  • Imaging3 Inc. IMGG (2)
  • ImaRx Therapeutics Inc. IMRX (2)
  • Immune Therapeutics Inc. IMUN (11)
  • Impact E-Solutions Corp. IESO (1)
  • Imperial Petroleum Inc. IPMN (10)
  • Inca Designs Inc. IDGI.PK (4)
  • Independent Film Development Corp. IFLM (1)
  • Index Oil and Gas Inc. IXOG.OB (5)
  • India Globalization Capital, Inc. IGC (21)
  • Industrial Biotechnology Corp. IBOT (1)
  • Infinite Group Inc. IMCI (48)
  • Inform Worldwide Holdings, Inc. IWWI (27)
  • InMed Pharmaceuticals, Inc. IMLFF (32)
  • Intec LTD ICLJY (1)
  • IntegraMed America Inc INMD (1)
  • Intelecom Inc. IECM (3)
  • Intelimax Media Inc. IXMD (31)
  • Intelligent Highway Solutions Inc. IHSI (6)
  • Intercept Energy Services Inc. IESCF (7)
  • Interleukin Genetics Inc. ILI (1)
  • International Barrier Technology Inc IBTGF (1)
  • International Consolidated Companies Inc. INCC (2)
  • International Stem Cell Corp. ISCO (226)
  • Inventergy Global Inc. INVT (15)
  • Investor Village (9)
  • Investors Business Daily (4)
  • InvestorsProfs (1)
  • InvestSource (11)
  • IPOs (8)
  • IR Biosciences Holdings Inc IRBS (3)
  • Isonics Corp. ISON (1)
  • ItsAboutFinance (2)
  • JC Data Solutions Inc. JCDS (4)
  • Joytoto USA Inc. JYTO (14)
  • JZZ Technologies Inc. JZZI (3)
  • KAL Energy Inc. KALG (3)
  • Kallo Inc. KALO (43)
  • Kandi Technologies Corp. KNDI (3)
  • KCM Holding Corp. KCMH (3)
  • Kingslake Energy Inc. KGLJ (2)
  • Klondex Mines Ltd. KLNDF (1)
  • Knobias KNBS (5)
  • Kootenay Zinc Corp. KTNNF (12)
  • Kraig Biocraft Laboratories Inc. KBLB (88)
  • L&L International Holdings Inc. LLFH (2)
  • Laguna Blends Inc. LAGBF (53)
  • Lantis Laser Inc. LLSR (5)
  • Last Mile Logistics Group LMLG (4)
  • Latitude 360 Inc. LATX (21)
  • LD Holdings Inc. LDHL (14)
  • Legacy Holdings Inc. LGYH (1)
  • Legacy Ventures International Inc. LGYV (24)
  • Legend Media Inc. LEGE (4)
  • Lexaria Bioscience Corp. LXRP (29)
  • Lifespan Inc. LSPN (1)
  • Lime Energy Corp. LIME (3)
  • Lingo Media Corp. LMDCF (18)
  • Linkwell Corporation LWLL (4)
  • Liquor Group Wholesale Inc. LIQR (22)
  • Loans4Less.com Inc. LFLS (47)
  • LOGIC Devices Inc. LOGC (1)
  • Logility Inc. LGTY (1)
  • LoJack Corp LOJN (3)
  • Longhai Steel Inc. LGHS (10)
  • LottoGopher Holdings Inc. LTTGF (10)
  • Lotus Pharmaceuticals Inc. LTUS (1)
  • Low Carbon Technologies (LWCTF) (3)
  • Lucas Energy, Inc. LEI (17)
  • Mabwe Minerals Inc. MBMI (56)
  • Macquarie Infrastructure Company MIC (5)
  • Maine and Maritime Corp. MMA (1)
  • Majic Wheels Corp. MJWL (6)
  • Makeup Inc. MAKU (2)
  • Mammoth Energy Group Inc. MMTE (5)
  • Mantra Venture Group Ltd. MVTG (10)
  • Marijuana Company of America, Inc. MCOA (4)
  • Mariner’s Choice International Inc. MCII (2)
  • Martin Nutraceuticals MNIU (11)
  • Material Technologies Inc. MTCH (44)
  • Max Media Group Inc. MXMI (9)
  • Max Sound Corp. MAXD (30)
  • MC Endeavors Inc. MSMY (2)
  • MedeFile International Inc. MDFI (46)
  • MediaG3 Inc. MDGC (1)
  • Medical Innovation Holdings, Inc. MIHI (4)
  • Medical Transcription Billing Corp. MTBC (13)
  • Medina International Holdings Inc. MIHI (3)
  • Medisafe 1 Technologies Corp. MFTH (3)
  • Medivisor Inc. MVSR (1)
  • Mega Media Group, Inc. MMDA (30)
  • MegaWest Energy Corporation MGWSF (2)
  • Memry Corp. MRY (2)
  • Metro One Development Inc. MODI (2)
  • Mexico Energy Corp. MXC (1)
  • MGX Minerals, Inc. MGXMF (6)
  • Micro Identification Technologies Inc. MMTC (44)
  • MicrocapMoney (2)
  • Microsoft Corporation MSFT (4)
  • Midway Gold Corp. MDW (1)
  • Military Resale Group MYRL (19)
  • Minco Silver Corp. MSV.TO (1)
  • Mindpix Corp. MNDP (1)
  • MIP Solutions Inc. MSOL (7)
  • MIT Holding MITD (36)
  • MitoPharm Corp. MTPH (1)
  • Mizati Luxury Alloy Wheels, Inc. MZTI (14)
  • Mobile Entertainment Inc. MBEI (1)
  • Mobile Lads Corp. MOBO (43)
  • Momentous Entertainment Group Inc. MMEG (19)
  • Monaker Group Inc. MKGI (48)
  • Money4Gold Holdings Inc. MFGD (3)
  • MortgageBrokers.com Holdings Inc. MBKR (2)
  • Mosquito Consolidated Gold Mines Limited MSQ.V (1)
  • Moxian Inc. MOXC (62)
  • mPhase Technologies Inc. XDSL (12)
  • MSE Enviro-Tech Corp. MEVT (4)
  • Muscle Flex Inc. MFLI (55)
  • MusclePharm Corp. MSLP (23)
  • Mvive Inc. MVIV (22)
  • My Automated Advisor (4)
  • MyECheck Inc. MYEC (99)
  • MyStaru.com Inc. MYST (1)
  • Nanogen Inc. NGEN (2)
  • Nanometrics Inc. NANO (1)
  • NanoSensors Inc. NNSR (1)
  • NanoTech Entertainment Inc. NTEK (30)
  • Napster, Inc. NAPS (5)
  • National Automation Services Inc. NASV (67)
  • National Coal Corp. NCOC (2)
  • National Waste Management Holdings Inc. NWMH (24)
  • Naturally Iowa Inc. NLIA (2)
  • NavStar Technologies Inc. NVSR (16)
  • nCoat Inc NCOA (8)
  • Neah Power Systems NPWZ (14)
  • Neohydro Technologies Corp. NHYT (4)
  • Neoprobe Corp. NEOP (6)
  • NeoStem Inc. NBS (6)
  • Net Element Inc. NETE (19)
  • NetSol Technologies Inc NTWK (64)
  • Neurobiological Technologies Inc. NTII (3)
  • NeuroMama Ltd. NERO (15)
  • Neutra Corp. NTRR (37)
  • New Asia Gold Corp. NWAG (1)
  • New Generation Biofuel Holdings Inc. GNB (3)
  • NewMarket China Inc. NMCH (7)
  • NewMarket Technology Inc. NMKT (7)
  • Newport Digital Technologies Inc. NPDT (61)
  • Nexia Holdings Inc. NXHD (51)
  • NexMed Inc. NEXM (8)
  • NeXplore Corp. NXPC (4)
  • Next One Interactive Inc. NXOI (7)
  • NextGen Bioscience Inc. NXGB (1)
  • NextPhase Wireless Inc. NPHS (1)
  • Nexus Enterprise Solutions Inc. NXES (30)
  • NF Energy Saving Corp. of America NFES (1)
  • Nhale Inc. NHLE (18)
  • Nilam Resources Inc. NILR (4)
  • Nitro Petroleum Inc. NTRO (5)
  • North Bay Resources Inc. NBRI (10)
  • NuTech Inc. NTCI (1)
  • Nutra Pharma Corp. NPHC (21)
  • NutraNomics Inc. NNRX (30)
  • NuVim Inc. NUVM (1)
  • NVIDIA Corp. NVDA (1)
  • NXGen Holdings Inc. NXGH (1)
  • Oakridge Global Energy Solutions Inc. OGES (63)
  • Obee's Franchise Systems Inc. OBFM (1)
  • OBJ Enterprises Inc. OBJE (27)
  • Odyne Corporation ODYC (15)
  • Omega Commercial Finance Corp. OCFN (2)
  • OmniaLuo Inc. OLUO (1)
  • Omnicity Corp. OMCY (26)
  • Omninet Media.Com, Inc. ONMC (5)
  • On The Go Healthcare Inc. MODI (13)
  • On the Move Systems Inc. OMVS (102)
  • Oncolin Therapeutics Inc. OCOL (1)
  • One Step Vending Corp. KOSK (2)
  • One World Holdings Inc. OWOO (61)
  • Ones to Watch (1,353)
  • Onstream Media Corp. ONSM (5)
  • Onteco Corp. ONTC (4)
  • Open Energy Corp. OEGY (4)
  • Optical Systems Inc. OPSY (2)
  • Oramed Pharmaceuticals Inc. ORMP (2)
  • Organic Alliance Inc. ORGC (2)
  • ORHub, Inc. ORHB (25)
  • OTCPicks.com (82)
  • OtcStockExchange (5)
  • OurPet's Company OPCO (78)
  • OxySure Systems Inc. OXYS (23)
  • P2 Solar Inc. PTOS (24)
  • Pacific Gold Corp. PCFG (3)
  • Pamplona Picks (1)
  • Pan Global Corp. PGLO (82)
  • PanGenex Corp. PGCX (3)
  • Paramount Gold and Silver Corp. PZG (3)
  • Patient Access Solutions Inc. PASO (7)
  • Patriot Energy Corp. dba TelTeck Solutions Inc PGYC.PK (11)
  • Patriot One Technologies, Inc. PTOTF (19)
  • Patriot Scientific Corp. PTSC (6)
  • Peace Arch Entertainment Group Inc. PAE (1)
  • Peoples Educational Holdings Inc. PEDH (2)
  • Perf Go Green Holdings Inc. PGOG (12)
  • Perfect Web Technologies, Inc PWBI (11)
  • Perfectenergy International Ltd. PFGY (1)
  • Performance Health Technologies Inc. PFMH (31)
  • Pet DRX Corp. VETS (1)
  • Petro Resources Corp. PRC (2)
  • PetroSun Inc. PSUD (41)
  • Phantom Fiber Corp. PHFB (2)
  • Pilot Financial Communications (3)
  • Pipex Pharmaceuticals Inc. PP (2)
  • PITOOEY! Inc. PTOO (14)
  • Planet Nutrition Inc. PNHL (4)
  • Platina Energy Group Inc. PLTG (8)
  • PlayBOX Inc. PYBX (5)
  • Players Network PNTV (15)
  • Pluristem Therapeutics Inc. PSTI (10)
  • Positron Corp. POSC (3)
  • PotNetwork Holding, Inc. POTN (15)
  • Power of the Dream Ventures (1)
  • Power Play Development Corp. PWPY (17)
  • Powersafe Technology Corp. PWSF (1)
  • Premier Energy Corp. PNRC (1)
  • Pressure BioSciences Inc. PBIO (41)
  • PRG Group Inc. PRGJ (2)
  • PrimEdge Inc. PEDI (1)
  • Private Equity Securities (93)
  • Pro Motors Group Corp. PMGU (2)
  • Pro Travel Network Inc. PTVL (2)
  • ProBility Media Corp. PBYA (33)
  • ProGaming Platforms Corp. PPTF (22)
  • Proginet Corp. PRGF (3)
  • Prom Resources PRMO (9)
  • Propalms Inc. PRPM (3)
  • Provectus Pharmaceuticals Inc. PVCT (12)
  • Puget Technologies Inc. PUGE (23)
  • Pulmo BioTech Inc. PLMO (4)
  • Puramed Bioscience Inc. PMBS (3)
  • Pure Biofuels Corp. PBOF (4)
  • Pure H2O Inc. PURH (1)
  • Pure Hospitality Solutions Inc. PNOW (99)
  • Purio Inc. PURO (5)
  • Puritan Financial Group Inc. PTNG (1)
  • Purple Beverage Company Inc. PPBV (8)
  • QED Connect Inc. QEDC (4)
  • Qiao Xing Universal Telephone Inc. XING (2)
  • QPC Lasers Inc. QPCI (3)
  • Qualcomm Inc. QCOM (2)
  • QualityStocks for Women (16)
  • QualityStocks Partner StockGuru (3,878)
  • QualityStocks Stock Newsletter (551)
  • QualityStocks Stock Newsletters (18,172)
  • QualityStocks Video Charts (286)
  • QualityStocks.net Market Basics (6)
  • QualityStocksNewsBreaks (216)
  • Quantum Fuel Systems Technologies Worldwide Inc. QTWW (15)
  • Quantum International Corp. QUAN (3)
  • Quasar Aerospace Industries Inc. QASP (6)
  • QuoteMedia Inc. QMCI (120)
  • Rafarma Pharmaceuticals Inc. RAFA (31)
  • Rainbow Coral Corp. RBCC (33)
  • Rancher Energy Corp. RNCH (9)
  • Raptor Resources Holdings Inc. RRHI (50)
  • Raven Gold Corp. RVNG (3)
  • Red Lake Exploration Inc. RLKX (19)
  • RegalWorks Media Inc. RWMI (4)
  • Regenicin, Inc. RGIN (6)
  • Reliant Financial Services Inc. RFNS (1)
  • Renhuang Pharmaceuticals Inc. RHGP (3)
  • ReoStar Energy Corp. REOS (1)
  • Resort Savers Inc. (RSSV) (10)
  • Revett Minerals (1)
  • RJD Green Inc. RJDG (3)
  • Rock Energy Resources Inc. RCKE (4)
  • Rodman & Renshaw (432)
  • Ronn Motor Company Inc. RNNM (6)
  • Rox Resources Ltd. RXRS (3)
  • Royal Quantum Group, Inc. RYQG (10)
  • Royal Standard Minerals Inc. RYSMF (2)
  • Rudy Nutrition RUNU (27)
  • RXi Pharmaceuticals Corp. RXII (3)
  • Santa Fe Gold Corp. SFEG (5)
  • Santa Fe Holding Company SFHD (3)
  • Save The World Air Inc. ZERO (12)
  • Savoy Energy Corp. SNVP (26)
  • SavWatt USA, Inc. SAVW (5)
  • Seabridge Gold Inc. SA (1)
  • Seawright Holdings Inc. SWRI (1)
  • Sector 10 Inc. SECI (78)
  • SES Solar Inc. SESI (2)
  • Seven Arts Pictures plc SAPX (1)
  • Seven Arts Pictures PLC SAPXF (5)
  • Shazam Stocks (22)
  • ShotPak Inc. SHTP (35)
  • Shumate Industries SHMTE (1)
  • Sibling Group Holdings Inc. SIBE (55)
  • Sierra Gold Corp. SGCP (2)
  • Signature Devices Inc. SDVI (9)
  • Silver Dragon Resources Inc. SDRG (1)
  • Silver Falcon Mining Inc. SFMI (1)
  • SilverSun Technologies Inc. SSNT (30)
  • Simtrol Inc. SMRL (74)
  • Simulated Environment Concepts Inc. SMEV (130)
  • Singlepoint Inc. SING (109)
  • Sino Agro Food Inc. SIAF (1)
  • Sinobiomed Inc. SOBM (4)
  • Sinovac Biotech Ltd SVC (1)
  • Sipp Industries Inc. SIPC (2)
  • Skinny Nutritional Corp. SKNY (19)
  • Skinvisible, Inc. SKVI (3)
  • Sky Petroleum Inc. SKPI (1)
  • SkyPostal Networks Inc. SKPN (66)
  • Small Cap Sentinel (2)
  • Small Cap Sleeper (3)
  • Smallcap Bullets (2)
  • Smallcaps.us (22)
  • SmallCapVoice (428)
  • Smoky Market Foods Inc. SMKY (9)
  • SocialPicks (1)
  • Sofame Technologies Inc SDW.V (1)
  • Sohm Inc. SHMN (14)
  • Solanex Management Inc. SLNX (15)
  • Solar Energy Initiatives Inc. SNRY (14)
  • Solar Wind Energy Tower Inc. SWET (15)
  • Solarfun Power Holdings Co. Ltd. SOLF (2)
  • Soul and Vibe Interactive Inc. SOUL (14)
  • South Sea Energy Corp. SSGY (7)
  • Soyo Group Inc SOYO (2)
  • SpaceDev Inc. SPDV (5)
  • Sparta Commercial Services Inc. SRCO (31)
  • Speedemissions Inc. SPMI (14)
  • Spicy Pickle Inc SPKL (18)
  • SpongeTech Delivery Systems Inc. SPNG (14)
  • Sports Pouch Beverage Company Inc. SPBV (1)
  • Star Mountain Resources Inc. SMRS (37)
  • Start Scientific Inc. STSC (22)
  • Stealth Technologies, Inc. STTH (3)
  • Stock Market E-News (1)
  • Stock Promoters (4)
  • StockEgg (14)
  • Stocks to Watch (1,920)
  • StocksJournal (2)
  • StockUPTicks (165)
  • Stockwire (6)
  • Strategic American Oil Corp SGCA (32)
  • Stratos Renewables Corp. SRNW (89)
  • StreamTrack Inc. STTK (31)
  • Striker Oil & Gas Inc. SOIS (4)
  • Sun Motor International Inc. SNMO (1)
  • SUN Sports & Entertainment Inc. SSPE (3)
  • Sunshine Biopharma Inc. SBFM (6)
  • Superlattice Power Inc. SLAT (60)
  • SupportSave Solutions, Inc. SSVE (10)
  • Surefect Holdings Inc. SUFH (1)
  • Suspect Detection Systems Inc. SDSS (37)
  • Sweet Success Enterprises Inc. SWTS (35)
  • Swiss Hawk AG SWHKF (1)
  • Symposium Production Corp. SYPJ (1)
  • Tactical Air Defense Services, Inc. TADF (15)
  • Tao Minerals Ltd. TAOL (1)
  • TapImmune, Inc. TPIV (15)
  • Tapinator, Inc. TAPM (3)
  • Taplmmune Inc. TPIM (1)
  • Technology Applications International Inc. NUUU (25)
  • TechPrecision Corp. TPCS (4)
  • Tecton Corp. TTNC (3)
  • Teknik Digital Arts Inc. TKNK (10)
  • Telanetix Inc. TNXI (2)
  • Teletouch Communications Inc. TLLE (5)
  • Terax Energy Inc. TEXG (32)
  • Terme Bancorp TMEB (1)
  • Terra Nostra Resources Corp. TNRO (25)
  • The Amergence Group AMNG (8)
  • The Aristocrat Group Corp. ASCC (113)
  • The Bowser Report (68)
  • The Bull Report (32)
  • The Capital Report (5)
  • The DIRECTV Group Inc. DTV (1)
  • The Fight Zone Inc. TFZI (12)
  • The Green Organic Dutchman Holdings Ltd. TGOD (3)
  • The Guitammer Company Inc. GTMM (38)
  • The International Traders Expo (30)
  • The Mobile Star Corp. MBST (7)
  • The Motley Fool (3)
  • The Mundus Group Inc. MNDS (1)
  • The Penny Stock Blog (28)
  • The Principal Structure Fund, Inc. PSF (2)
  • The Tracking Corp. TRKG (1)
  • The UpTurn, Inc. UPTR (20)
  • The Wall Street Savant (24)
  • The Wide Angle (3)
  • Thresher Industries Inc. THRR (15)
  • Tidelands Oil and Gas Corp. TIDE (1)
  • Tiens Biotech Group USA Inc. TBV (1)
  • TMT Capital Corp. TMTP (1)
  • TNI BioTech Inc. TNIB (16)
  • Tombstone Exploration Corp. TMBXF (9)
  • TOMI Environmental Solutions Inc. TOMZ (4)
  • Tootie Pie Company, Inc. TOOT (11)
  • Torchlight Energy Resources, Inc. TRCH (2)
  • TradeShow Marketing Company Inc. TSHO (21)
  • TransWorldNews (4)
  • Tri-Star Holdings Inc. TSHL (31)
  • Trimax Corp. TMXN (31)
  • TripleCrownStocks (9)
  • True 2 Beauty Inc. TRTB (43)
  • TwinTrader (8)
  • TXP Corporation TXPO (1)
  • TZ Ltd. TZL.AX (1)
  • U.S. Mine Makers Inc. USMM (1)
  • uKarma Corporation UKMA (1)
  • Ultitek Ltd. UITK (21)
  • Unbridled Energy Corporation TSX-UNE (21)
  • Unico Inc. UNCO (3)
  • Universal Bioenergy Inc. UBRG (3)
  • Universal Detection Technology UNDT (41)
  • Universal Energy Corp. UVSE (19)
  • Universal Property Development and Acquisition UPDA (4)
  • Universal Tracking Solutions Inc. UTRK (13)
  • Universal Travel Group UTVG (14)
  • UpSNAP Inc. UPSN (1)
  • Uranium Energy Corp. UEC (64)
  • Uranium Hunter Corp. URHN (17)
  • Urex Energy Corp. URXE (1)
  • USA Recycling Industries Inc. USRI (21)
  • USA Superior Energy Inc. USSU (9)
  • Ustelematics Inc. UTLM (27)
  • Utah Uranium Corp. UTUC (2)
  • Utilicraft Aerospace Industries Inc. UITA (2)
  • ValueRich & iValueRich (9)
  • Vaporin Inc. VAPOD (2)
  • VentriPoint Diagnostics Ltd. VPTDF (26)
  • Vermillion Inc. VRML (3)
  • Vertical Branding Inc. VBDG (11)
  • VIASPACE, Inc. VSPC (185)
  • Victory Energy Corp. VYEY (29)
  • Vidshadow Inc. VSHD (1)
  • View Systems Inc. VSYM (16)
  • Viper Networks Inc. VPER (2)
  • Viral Genetics Inc. VRAL (3)
  • Viropro International Inc. VPRO (2)
  • VirTra Systems Inc. VTSI (22)
  • Viscount Systems Inc. VSYS (27)
  • visionGATEWAY Inc. VGWA (1)
  • VistaGen Therapeutics Inc. VSTA (104)
  • Visualant Inc. VSUL (5)
  • Vital Products Inc. VTLP (5)
  • Viyya Technologies Inc. VYON (2)
  • VizStar Inc VIZS (24)
  • Voiceserve Inc. VSRV (18)
  • Vortex Resources Corp. VTEX (7)
  • Vsurance Inc. VSUR (3)
  • Vyteris Inc. VYHN (1)
  • W2 Energy Inc. WWEN (13)
  • Wall Street News Alert (76)
  • WallStreetGrapevine (12)
  • WaterPure International Inc. WPUR (4)
  • Wave Systems Corp. WAVX (5)
  • Week in Review (2)
  • Well Power Inc. WPWR (77)
  • Wescorp Energy Inc. WSCE (18)
  • West Canyon Energy Corp. WCYO (1)
  • Western Standard Energy Corp. WSEG (7)
  • Who's Your Daddy Inc. WYDI (7)
  • WikiLoan Inc. WKLI (14)
  • Wind Energy America Inc. WNEA (3)
  • Wisdom Homes of America Inc. WOFA (15)
  • Wits Basin Precious Minerals Inc. WITM (2)
  • Woize International Ltd. WOIZ (1)
  • WordLogic Corp. WLGC (40)
  • Workstream Inc. WSTM (9)
  • WorldWater & Solar Technologies Corp. WWAT (10)
  • Worldwide Energy and Manufacturing WEMU (12)
  • Worldwide Manufacturing USA Inc. WWMU (6)
  • WRIT Media Group Inc. WRIT (36)
  • X-Change Corp. (XCHC) (2)
  • Xaar Plc XAARF (1)
  • Xenomics Inc. XNOM (1)
  • XsunX Inc. XSNX (17)
  • XZERES Corp. XPWR (2)
  • Younger America YNGR (13)
  • Zacks Investment Research (11)
  • ZAGG Inc. ZAGG (9)
  • Zaldiva Inc. ZLDV (3)
  • ZAP ZAAP (15)
  • ZBB Energy Corp ZBB (7)
  • Zenosense Inc. ZENO (53)
  • Zentric Inc. ZNTR (14)
  • Zevotek Inc. ZVTK (8)
  • Znomics Inc. ZNOM (3)
  • Newsletter Signup

    Stay ahead of the pack with QualityStocks and receive "The QualityStocks Daily", our summary formatted newsletter containing stock tips from hundreds of online investment newsletters.

    Rotate your device 90° to view site.